Bile Ducts, Intrahepatic
Adenocarcinoma of the common hepatic duct bifurcation. These tumors are generally small, sharply localized, and seldom metastasizing. G. Klatskin's original review of 13 cases was published in 1965. Once thought to be relatively uncommon, tumors of the bifurcation of the bile duct now appear to comprise more than one-half of all bile duct cancers. (From Holland et al., Cancer Medicine, 3d ed, p1457)
Bile Ducts, Extrahepatic
Hepatic Duct, Common
Infection of the biliary passages with CLONORCHIS SINENSIS, also called Opisthorchis sinensis. It may lead to inflammation of the biliary tract, proliferation of biliary epithelium, progressive portal fibrosis, and sometimes bile duct carcinoma. Extension to the liver may lead to fatty changes and cirrhosis. (From Dorland, 27th ed)
Cholangiopancreatography, Endoscopic Retrograde
Biliary Tract Neoplasms
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
Cholangiopancreatography, Magnetic Resonance
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Tumor Markers, Biological
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Lobar decrease in 99mTc-GSA accumulation in hilar cholangiocarcinoma. (1/1040)Hilar cholangiocarcinoma can obstruct hepatic ducts and involve the portal veins. Both biliary stasis and decrease in portal venous flow are known to reduce 99mTc-diethylenetriamine pentaacetic acid-galactosyl human serum albumin (GSA) accumulation. The specific relationship between these pathological conditions due to hilar cholangiocarcinomas and 99mTc-GSA accumulation has never been clarified. METHODS: Sixteen patients with hilar cholangiocarcinomas who underwent 99mTc-GSA liver scintigraphy were reviewed. The relationship between significant decrease in 99mTc-GSA accumulation and lobar biliary stasis, or decrease in the portal venous flow, was evaluated. Average counts of region of interest placed in both right and left lobes were compared in the same transaxial SPECT section. Count ratios of right and left lobes were calculated. RESULTS: Significant lobar decrease in 99mTc-GSA accumulation was observed in 6 of the 16 patients. Ipsilateral portal venous stenosis or obstruction was seen in all these 6 patients, whereas ipsilateral portal venous stenosis or obstruction was seen in only 1 of the other 10 patients. Symmetric bile duct dilatation was seen in 13 patients, and asymmetric bile duct dilatation was seen in 3. Lobar decrease in 99mTc-GSA accumulation correlated well with decrease in ipsilateral portal venous flow (P < 0.0005). The count ratio was significantly reduced when unilateral portal venous flow decreased (P < 0.05). CONCLUSION: Using 99mTc-GSA liver scintigraphy, we can predict lobar decrease in ipsilateral portal venous flow and monitor hepatic functional lateralities in patients with hilar cholangiocarcinomas. (+info)
Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines. (2/1040)Cholangiocarcinoma (CCA), a tumour of the bile duct epithelium, occurs with a higher incidence in South-east Asian countries than in Europe and North America. The prognosis is poor, due to the unavailability of early diagnosis and the tumours being relatively resistant to chemotherapy. In the present study one of the fatal routes of this tumour was studied. This death was stimulated by TNF-alpha. TNF-alpha at a concentration of 760 pg/ml and 100 pg/ml in the presence of 1 microgram/ml actinomycin D induced 50% cell death of the two established human cholangiocarcinoma cell lines HuCCA-1 and HuCCA-INu, respectively. Preincubation of both cell lines with MoAb to TNF-RI or TNF-RII before TNF-alpha treatment showed that only the MoAb specific to TNF-RI inhibited death. The death of these two cell lines was proved to be apoptosis. Western blot analysis of extracts from both cell lines demonstrated a cleavage of poly (ADP-ribose) polymerase (PARP) within 6-8 h following TNF-alpha treatment. The degradation of PARP was prevented by a MoAb to TNF-RI indicating that the TNF-RI but not TNF-RII was involved in TNF-induced apoptosis in these two human cholangiocarcinoma cell lines. Moreover, peptide inhibitor for caspase II subfamily, Ac-DEVD-CHO, reduced the cytolysis of TNF-alpha-treated cholangiocarcinoma cells. The inhibitor also prevented degradation of PARP. These results indicate that the interaction between TNF-alpha and TNF-RI alone generated a sufficient signal to activate a caspase II subfamily-dependent apoptosis in human cholangiocarcinoma cell lines. (+info)
Lymph node metastasis in intrahepatic cholangiocarcinoma. (3/1040)BACKGROUND: Lymph node metastasis is a significant prognostic factor in intrahepatic cholangiocarcinoma. This study was aimed at investigating lymph node metastasis in intrahepatic cholangiocarcinoma and to examine whether the extent of metastasis affects outcomes after surgery. METHODS: From 1980 through 1996, 70 patients with intrahepatic cholangiocarcinoma underwent hepatectomy, with a 50% curative resection rate. Lymph node dissection was performed in 51 patients, and the presence of lymph node metastasis was examined microscopically. The metastatic nodes were divided into groups N1, N2 or N3 using the classification proposed by the Liver Cancer Study Group of Japan. RESULTS: Twenty-three patients had lymph node metastasis. Metastasis was to N1 nodes in 10 patients, to N2 nodes in nine patients and to N3 nodes in four patients. Nineteen patients had metastatic nodes in the hepatoduodenal ligament, which was the most common metastatic site regardless of tumor location. The five-year survival rate in patients with lymph node metastasis (0%) was significantly lower (p < 0.0001) than that in patients without lymph node metastasis (51 %); however, five-year survival rates did not differ between patients with metastases to N1, N2 and N3 nodes. CONCLUSIONS: Lymph nodes in the hepatoduodenal ligament may be sentinel nodes for intrahepatic cholangiocarcinoma, and outcomes after surgery for patients with lymph node metastasis are poor regardless of the sites of nodal metastasis. (+info)
Promoting effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone on rat glandular stomach carcinogenesis initiated with N-methyl-N'-nitro-N-nitrosoguanidine. (4/1040)The modifying effects of 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), a mutagenic by-product in chlorinated water, on the development of glandular stomach cancers were investigated in Wistar rats. A total of 120 males, 6 weeks of age, were divided into six groups. After initiation with 100 ppm N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) solution and 5% NaCl diet for 8 weeks, 30 rats each in groups 1-3 were given MX in the drinking water at concentrations of 30, 10, or 0 ppm for the following 57 weeks. Ten animals each in groups 4-6 were administered the MX without prior carcinogen exposure. There were no statistical significant differences in final body weights between the groups. The incidences and multiplicities of adenocarcinomas in the glandular stomachs were significantly higher (P < 0.05) in the initiated 30 ppm MX group than those in the MNNG/NaCl group. The incidences of atypical hyperplasias in the glandular stomachs were also significantly increased (P < 0.05 or 0.01) by the MX treatments. With their multiplicity, the effects were clearly dose dependent. Interestingly, the 30 ppm MX alone itself induced atypical hyperplasias in the pylorus, although the incidences and severity were low. Moreover, MX showed a tendency to enhance the development of intrahepatic cholangiocellular tumors and thyroid follicular cell tumors in the MNNG-treated animals. The results of the present study thus indicate that MX exerts promoting effects when given during the postinitiation phase of two-stage glandular stomach carcinogenesis in rats. (+info)
Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver. (5/1040)p73, the first homologue of the tumour suppressor protein p53, was recently discovered on chromosome 1p36 and has been shown to induce apoptosis in a p53-like manner. The present study was performed with the aim of investigating the expression of p53, its new homologue p73 and the occurrence of apoptosis in cholangiocellular carcinoma. Protein levels of p73 were examined in 41 patients with curatively (R0-) resected cholangiocellular carcinomas with an antiserum, raised against a peptide in the N-terminal domain of p73. The incidence of mutations in the p53 gene was analysed by direct sequencing and also immunohistochemically. Apoptotic cell death was assessed using in-situ end-labelling (ISEL) technique in combination with morphological criteria. The results obtained were correlated with patient survival. Immunostaining of p73 protein was detected in 17/41 carcinomas examined (41%). The immunoreactivity was confined to the cell nucleus. In 15/41 patients (37%), mutations of the p53 gene were observed. Eleven out of these 15 patients stained also positive for p73. In contrast, out of 26 patients without any detectable p53 mutation, only six exhibited p73 immunostaining. We failed to observe a correlation between p73 expression or p53 and apoptosis within a given tumour. Survival analysis including the parameters stage and grade of disease, p73 and p53, and also apoptosis, showed that tumour stage and grade as well as p53 and p73 were significantly related to prognosis. In Cox regression survival analysis, however, only extent of primary tumour and lymph node status had an independent prognostic impact. Our results with a high prevalence of p73 within tumours harbouring mutated p53 gene suggest that p73 could compensate for p53 function. We failed to establish p73 or p53 as independent prognostic factors in cholangiocellular carcinoma of the liver. (+info)
Intrahepatic peripheral cholangiocarcinoma: CT features in 18 pathologically proven cases. (6/1040)OBJECTIVE: To determine the morphological features of 18 pathologically proven intrahepatic peripheral cholangiocarcinoma (IHPCC) cases in computerized tomography (CT) image. METHODS: All 18 patients had CT, using Picker I.Q.T/C and taking pre-contrast continuous 10-mm sections throughout the liver and post-contrast continuous 10-mm sections throughout the focuses. RESULTS: The disease was characterized in CT image by the following: all focuses were found in the periphery of the liver and shown as a lobulated or fused hypodense space-occupying mass; there were one or more divergent or confluent, circular or irregular cystic areas with much lower density, in the majority. All focuses could be enhanced slightly and most revealed a dim edge. Dilated bile ducts around the focus were found frequently; the dilated bile ducts especially seemed to encircle the focus (33.3%, 6/18). This phenomenon were referred to as "encysted sign of dilated bile ducts". CONCLUSIONS: CT scanning should be one of the most important investigative methods for IHPCC due to the disease characteristics identified in CT image, especially "encysted sign of dilated bile ducts" which possesses specificity in diagnosing the disease. (+info)
Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. (7/1040)We have previously demonstrated that tamoxifen inhibits the growth of human cholangiocarcinoma cells in culture and inhibits tumor growth when cells are injected into nude mice. However, the mechanism of action of tamoxifen remains unknown. Here we demonstrate that tamoxifen and trifluoperazine, both potent calmodulin antagonists, induce apoptosis in vitro, probably acting via the Fas system, in human cholangiocarcinoma cells. Human cholangiocarcinoma cell lines heterogeneously express Fas antigen on their surface. Fas-negative and Fas-positive surface-expressing cells were isolated, cloned, and cultured. Fas antibody, tamoxifen, and trifluoperazine induced dose-dependent apoptosis only in Fas-positive cells; Fas-negative cells were unaffected. Furthermore, apoptosis induced by tamoxifen in Fas-positive cells was blocked by an inhibitory Fas antibody. Tamoxifen was not acting through an anti-estrogenic mechanism, because neither Fas-negative nor Fas-positive cells expressed estrogen receptors and the pure anti-estrogen compound, ICI 182780, did not induce apoptosis in either cell line. Fas-negative cells, but not Fas-positive cells, were able to produce tumors when subcutaneously injected into nude mice. These findings suggest Fas may be a candidate oncogene involved in the pathogenesis of cholangiocarcinoma. Furthermore, the similarity between the pro-apoptotic effects of tamoxifen and trifluoperazine support an underlying molecular mechanism for Fas-mediated apoptosis that involves calmodulin. (+info)
Recurrent thrombo-embolic episodes: the association of cholangiocarcinoma with antiphospholipid syndrome. (8/1040)Antiphospholipid syndrome is a disorder of recurrent vascular thrombosis, pregnancy loss and thrombocytopenia associated with persistently elevated levels of antiphospholipid antibodies. It was first described in a group of patients with systemic lupus erythematosus but has since been associated with a wide range of conditions, including other autoimmune disorders and malignancy. It can also occur in isolation, the so-called primary antiphospholipid syndrome. We describe an elderly woman with the antiphospholipid syndrome thought to be associated with a cholangiocarcinoma. (+info)
Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma<...
TY - JOUR. T1 - Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. AU - Boehm, Lucas M.. AU - Jayakrishnan, Thejus T.. AU - Miura, John T.. AU - Zacharias, Anthony J.. AU - Johnston, Fabian M.. AU - Turaga, Kiran K.. AU - Gamblin, T. Clark. PY - 2015/2/1. Y1 - 2015/2/1. N2 - Background: Hepatic artery based therapies (HAT) are offered for patients with unresectable intrahepatic cholangiocarcinoma (ICC). We aimed to evaluate the comparative effectiveness of HAT-hepatic arterial infusion (HAI), transcatheter arterial chemoembolization (TACE), drug-eluting bead TACE (DEB-TACE), and Yttrium90 radioembolization (Y-90) for unresectable ICC. Methods: A meta-analysis was performed using a prospectively registered search strategy at PROSPERO (CRD42013004830) that utilized PubMed (2003-2013). Primary outcome was median overall survival (OS), and secondary outcomes were tumor response to therapy and toxicity. Results: A total of 20 articles (of ...
Cholangiocarcinoma cells are dependent on antiapoptotic signaling for survival and resistance to death stimuli - UCHL1...
Cholangiocarcinoma cells are dependent on antiapoptotic signaling for survival and resistance to death stimuli. to contribute to the effects of embelin on cholangiocarcinoma cells. Instead, embelin caused inhibition of cell proliferation and cell cycle analysis indicated that embelin increased the number of cells in S and G2/M phase. Our results demonstrate that embelin decreased VD2-D3 proliferation in cholangiocarcinoma cell lines. Embelin treatment resulted in decreased XIAP protein expression, but did not induce or enhance apoptosis. Thus, in cholangiocarcinoma cells the mechanism of action of embelin is probably not reliant on apoptosis. Introduction Cholangiocarcinoma can be a liver organ tumor with mobile top features of bile duct epithelial cells and may be the second most common major liver cancers. Biliary tract swelling predisposes to cholangiocarcinoma, although most individuals dont have identified underlying liver disease at the proper time of diagnosis. Chemotherapy offers been ...
Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion<...
TY - JOUR. T1 - Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. AU - DeMorrow, Sharon. AU - Onori, Paolo. AU - Venter, Julie. AU - Invernizzi, Pietro. AU - Frampton, Gabriel. AU - White, Mellanie. AU - Franchitto, Antonio. AU - Kopriva, Shelley. AU - Bernuzzi, Francesca. AU - Francis, Heather. AU - Coufal, Monique. AU - Glaser, Shannon. AU - Fava, Giammarco. AU - Meng, Fanyin. AU - Alvaro, Domenico. AU - Carpino, Guido. AU - Gaudio, Eugenio. AU - Alpini, Gianfranco. PY - 2011/5. Y1 - 2011/5. N2 - No information exists on the role of neuropeptide Y (NPY) in cholangiocarcinoma growth. Therefore, we evaluated the expression and secretion of NPY and its subsequent effects on cholangiocarcinoma growth and invasion. Cholangiocarcinoma cell lines and nonmalignant cholangiocytes were used to assess NPY mRNA expression and protein secretion. NPY expression was assessed by immunohistochemistry in human liver biopsies. Cell proliferation and migration were evaluated in vitro by MTS ...
Intrahepatic Cholangiocarcinoma (ICCA) Market Size, Share, Trends, Competitive Assessment, Market Forecast and Research Report...
Request for sample pages of the report: https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-market. Intrahepatic Cholangiocarcinoma (ICCA) Emerging Therapies:. 1. Pemazyre (Pemigatinib): Incyte Corporation. 2. Rozlytrek (Entrectinib): Roche. 3. Melphalan/HDS: Delcath Systems. 4. Derazantinib: Basilea Pharmaceutica. Intrahepatic Cholangiocarcinoma (ICCA) Market Outlook. Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.. Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and ...
Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Outcome after liver transplantation<...
TY - JOUR. T1 - Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma. T2 - Outcome after liver transplantation. AU - Maganty, Kishore. AU - Levi, David. AU - Moon, Jang. AU - Bejarano, Pablo A.. AU - Arosemena, Leopoldo. AU - Tzakis, Andreas. AU - Martin, Paul. PY - 2010/12/1. Y1 - 2010/12/1. N2 - Background: Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma is a rare hepatobiliary malignancy incorporating components derived from both hepatocyte and intrahepatic bile duct epithelium. The natural history, treatment, and prognosis of this distinct cancer differ from hepatocellular carcinoma (HCC) or cholangiocarcinoma (CC) and are not completely understood. There is considerable controversy about the classification, treatment, and survival, which in turn is related to the rarity of the condition. Treatment options include surgical resection and the prognosis is believed to be better than CC but worse than HCC alone. Methods: We report a single-center liver ...
Histopathological characteristics of hypervascular cholangiocellular carcinoma as an early stage of cholangiocellular carcinoma...
TY - JOUR. T1 - Histopathological characteristics of hypervascular cholangiocellular carcinoma as an early stage of cholangiocellular carcinoma. AU - Sato, Yuya. AU - Ojima, Hidenori. AU - Onaya, Hiroaki. AU - Mori, Taisuke. AU - Hiraoka, Nobuyoshi. AU - Kishi, Yoji. AU - Nara, Satoshi. AU - Esaki, Minoru. AU - Shimada, Kazuaki. AU - Kosuge, Tomoo. AU - Sugihara, Kenich. AU - Kanai, Yae. PY - 2014/10/1. Y1 - 2014/10/1. N2 - Aim: Prognosis of hypervascular cholangiocellular carcinoma (h-CCC) is reportedly better than that of ordinary hypovascular CCC (o-CCC). The aim of this study is to clarify the histopathological characteristics of h-CCC. Methods: On the basis of the findings in the arterial phase of contrast-enhanced computed tomography, 16 cases of mass-forming-type CCC were divided into two groups (h-CCC, n=8; o-CCC, n=8). Areas of high (Area H-a) and low (Area H-b) attenuation in h-CCC cases and areas of low attenuation in o-CCC cases (Area O) were delineated. These areas were then ...
Inflammatory Cytokines Induce DNA damage and Inhibit DNA repair in Cholangiocarcinoma Cells by a Nitric Oxide-dependent...
The original observations of this study relate to inflammation, NO production, DNA damage, and inhibition of DNA repair as related mechanisms for the development and/or progression of cholangiocarcinoma. Our results directly demonstrate the following: (a) human cholangiocarcinomas express the iNOS protein; (b) proinflammatory cytokines stimulate iNOS message and protein expression and the production of NO in cholangiocarcinoma cell lines; (c) the magnitude of NO produced is sufficient to cause single-stranded, double-stranded, and oxidative DNA lesions in the malignant cell lines; and (d) stimulated NO generation is associated with impaired global DNA repair activity in the cholangiocarcinoma cell lines. These data suggest that NO generated in response to inflammation may initiate malignant transformation of biliary epithelia and/or promote progression of established cholangiocarcinoma. Each of these observations is discussed in greater detail below.. iNOS expression with NO generation has been ...
Adjuvant Regimen Produces Good Survival Results in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma - The ASCO Post
In a phase II Intergroup study (SWOG S0809) reported in the Journal of Clinical Oncology, Ben-Josef et al found that adjuvant capecitabine and gemcitabine followed by concurrent radiotherapy and capecitabine produced good survival results in patients with extrahepatic cholangiocarcinoma or gallbladder carcinoma.. Study Details. The study included 79 patients who had undergone radical resection and had stage pT2-4 or N+ or positive resection margins, M0, and a Zubrod performance status of 0 to 1. Patients received four cycles of gemcitabine 1,000 mg/m2 on days 1 and 8 and capecitabine 1,500 mg/m2/d on days 1 to 14 every 21 days followed by concurrent capecitabine 1,330 mg/m2/d and radiotherapy consisting of 45 Gy to regional lymphatics and 54 to 59.4 Gy to the tumor bed. The study was designed to estimate 2-year survival overall after R0 or R1 resection.. Of the 79 patients, 68% had extrahepatic cholangiocarcinoma, and 32% had gallbladder carcinoma; 68% had R0 resection, and 32% had R1 ...
IJMS | Free Full-Text | RNA Interference Targeting Slug Increases Cholangiocarcinoma Cell Sensitivity to Cisplatin via...
Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated modulator of apoptosis) and it has recently been demonstrated that Slug plays an important role in controlling apoptosis. In this study, we examined whether Slugs ability to silence expression suppresses the growth of cholangiocarcinoma cells and/or sensitizes cholangiocarcinoma cells to chemotherapeutic agents through induction of apoptosis. We targeted the Slug gene using siRNA (Slug siRNA) via full Slug cDNA plasmid (Slug cDNA) transfection of cholangiocarcinoma cells. Slug siRNA, cisplatin, or Slug siRNA in combination with cisplatin, were used to treat cholangiocarcinoma cells in vitro. Western blot was used to detect the expression of Slug, PUMA, and E-cadherin protein. TUNEL, Annexin V Staining, and cell cycle analysis were used to detect apoptosis. A nude mice subcutaneous xenograft model of QBC939 cells was used to assess the effect of Slug silencing and/or cisplatin on tumor growth. Immunohistochemical staining was used
Epstein-Barr virus-associated intrahepatic cholangiocarcinoma bearing an intense lymphoplasmacytic infiltration | Journal of...
Lymphoepithelioma-like carcinoma (LELC) of the liver is extremely rare. To our knowledge, only 16 cases of pure LELC or LELC with ordinary adenocarcinoma arising in the hepatobiliary tract have been reported in the English literature.1-7 Most of these tumours (68%, 11/16) were positive for Epstein-Barr virus (EBV) by EBV-encoded small non-polyadenylated RNA (EBER-1) in situ hybridisation.1-6 However, association of intrahepatic cholangiocarcinoma bearing an intense lymphoplasmacytic infiltration with EBV infection has not been reported. We were the first to present two cases of intrahepatic cholangiocarcinoma with dense lymphoplasmacytic infiltration from Southern China, an area that is well known for and has a high-incidence of nasopharyngeal carcinoma, showing EBV infection, but one case of LELC was associated with EBV infection as well. ...
Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma
Conditions: Adenocarcinoma; Adenocystic Carcinoma; Anal Cancer; Appendix Cancer; Brain Tumor; Glioblastoma; Astrocytoma; Bile Duct Cancer; Cholangiocarcinoma; Bladder Cancer; Bone Cancer; Synovial Sarcoma; Chondrosarcoma; Liposarcoma; Sarcoma, Kaposi; Sarcoma,Soft Tissue; Sarcoma; Osteosarcoma; CNS Cancer; Brain Stem Neoplasms; Breast Cancer; Cervical Cancer; Colorectal Cancer; Rectal Cancer; Colon Cancer; Esophageal Cancer; Esophagus Cancer; Cancer of Colon; Pancreatic Cancer; Cancer of Pancreas; Testis Cancer; Testicular Cancer; Ureter Cancer; Renal Cell Carcinoma; Kidney Cancer; Gestational Trophoblastic Tumor; Head and Neck Neoplasms; Parotid Tumor; Larynx Cancer; Tongue Cancer; Pharynx Cancer; Salivary Gland Cancer; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Multiple Myeloma; Non Hodgkin Lymphoma; Carcinoid Tumor; Lung Cancer; Neuroendocrine Tumors; Mesothelioma; Thyroid Cancer; Parathyroid Neoplasms; Adrenal Cancer; Small Bowel Cancer; Stomach Cancer; ...
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: A multi-institutional analysis of 305 cases<...
TY - JOUR. T1 - The impact of portal vein resection on outcomes for hilar cholangiocarcinoma. T2 - A multi-institutional analysis of 305 cases. AU - De Jong, Mechteld C.. AU - Marques, Hugo. AU - Clary, Bryan M.. AU - Bauer, Todd W.. AU - Marsh, J. Wallis. AU - Ribero, Dario. AU - Majno, Pietro. AU - Hatzaras, Ioannis. AU - Walters, Dustin M.. AU - Barbas, Andrew S.. AU - Mega, Raquel. AU - Schulick, Richard D.. AU - Choti, Michael A.. AU - Geller, David A.. AU - Barroso, Eduardo. AU - Mentha, Gilles. AU - Capussotti, Lorenzo. AU - Pawlik, Timothy M.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - BACKGROUND. Surgical strategy for hilar cholangiocarcinoma often includes hepatectomy, but the role of portal vein resection (PVR) remains controversial. In this study, the authors sought to identify factors associated with outcome after surgical management of hilar cholangiocarcinoma and examined the impact of PVR on survival. METHODS: Three hundred five patients who underwent curative-intent surgery for hilar ...
Molecular Pathogenesis of Cholangiocarcinoma | BMC Cancer | Full Text
Cholangiocarcinomas are a heterogeneous group of malignancies arising from a number of cells of origin along the biliary tree. Although most cases in Western countries are sporadic, large population-based studies have identified a number of risk factors. This review summarises the evidence behind reported risk factors and current understanding of the molecular pathogenesis of cholangiocarcinoma, with a focus on inflammation and cholestasis as the driving forces in cholangiocarcinoma development. Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma. Certain bacterial, viral or parasitic infections such as hepatitis B and C and liver flukes also increase cholangiocarcinoma risk. Other risk factors include inflammatory disorders (such as inflammatory bowel disease and chronic pancreatitis), toxins (e.g. alcohol and tobacco), metabolic conditions (diabetes, obesity and non
Forest plot of extrahepatic cholangiocarcinoma risk ass | Open-i
Forest plot of extrahepatic cholangiocarcinoma risk associated with HCV infection. The pooled risk estimate was 1.75 (95% CI, 1.00 to 3.051).
Identiﬁcation of Homer1 as a Potential Prognostic Marker for Intrahepatic Cholangiocarcinoma
Background: The aim of the present study was to analyze whether Homer1 is a potential prognostic markerfor intrahepatic cholangiocarcinoma (ICC). Materials and Methods: The expression of Homer1 in ICC tissuewas detected with immunohistochemistry and levels of protein in ICC and paratumor tissues were evaluated byWestern blotting. Survival analysis by the Kaplan-Meier method was performed to assess prognostic significance.Results: Homer1 expression was high in 67.4% (58/86) of ICC samples, and there was significant differencebetween ICC and adjacent noncancerous tissues (p|0.001); high expression was associated with poor histologicdifferentiation (p=0.019), TNM stage (p=0.014), lymph node metastasis (p=0.040), and lymphatic invasion(p=0.025). On Kaplan-Meier analysis, a comparison of survival curves of low versus high expressors of Homer1revealed a highly significant difference in OS (p=0.001) and DFS (p=0.006), indicating that high expressionof Homer1 was linked with a worse prognosis. Multivariate
Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18 F-FDG-PET is associated with the KRAS...
Surgical resection remains the mainstay of curative treatment for intrahepatic cholangiocarcinoma (ICC). Prognosis after surgery is unsatisfactory despite improvements in treatment and post-operative clinical management. Despite developments in the molecular profiling of ICC, the preoperative prediction of prognosis remains a challenge. This study aimed to identify clinical prognostic indicators by investigating the molecular profiles of ICC and evaluating the preoperative imaging data of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). A retrospective analysis was performed on 50 consecutive patients with ICC who underwent curative hepatectomy after 18F-FDG-PET examination. To evaluate the molecular profiles of ICC, KRAS mutation status was assessed in resected specimens. For the assessment of glucose uptake, we observed the expression of glucose transporter-1 (GLUT-1) by immunohistochemistry. The data of 18F-FDG-PET were re-evaluated as follows: maximum standardized uptake value,
Establishment of a prediction model of intrahepatic cholangiocarcinoma with lymph node metastases based on CT combined with...
Overview: In view of the increasing morbidity and mortality rates of Intrahepatic Cholangiocarcinoma (ICC) and the high risk of lymph node metastasis,..
Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: A cohort study of parous...
Few studies have evaluated the risk of cancers other than hepatocellular carcinoma associated with hepatitis B virus (HBV) infection. This study aimed to estimate incidence rates of intrahepatic cholangiocarcinoma (ICC) and non-Hodgkin lymphoma (NHL) and its major subtypes in a nationwide cohort of parous women and to assess their associations with chronic HBV infection. We conducted a cohort study including 1,782,401 pregnant Taiwanese women whose HBV serostatus was obtained from the National Hepatitis B Vaccination Registry. Newly diagnosed ICCs and NHLs were ascertained through data linkage with the National Cancer Registry. Risks of ICC and NHL were assessed using Cox proportional hazards regression models. After a mean of 6.91 years of follow-up, there were 18 cases of ICC and 192 cases of NHL, including 99 cases of diffuse large B-cell lymphoma (DLBCL). Incidence rates of ICC were 0.09 and 0.43 per 100,000 person-years, respectively, among women who were hepatitis B surface antigen ...
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation | BMC Cancer | Full Text
Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective chemo and targeted therapies. Cell lines and animal models, even partially reflecting tumor characteristics, have limits to study ICC biology and drug response. In this work, we created and characterized a novel ICC patient-derived xenograft (PDX) model of Italian origin. Seventeen primary ICC tumors derived from Italian patients were implanted into NOD (Non-Obese Diabetic)/Shi-SCID (severe combined immunodeficient) mice. To verify if the original tumor characteristics were maintained in PDX, immunohistochemical (cytokeratin 7, 17, 19, and epithelial membrane antigen) molecular (gene and microRNA expression profiling) and genetic analyses (comparative genomic hybridization array, and mutational analysis of the kinase domain of EGFR coding sequence, from exons 18 to 21, exons 2 to 4 of K-RAS, exons 2 to 4 of N-RAS, exons 9 and 20 of PI3KCA, and exon 15 of B-RAF) were performed after tumor stabilization.
Enhancement patterns of intrahepatic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced...
The aim of this study was to compare the enhancement pattern of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) with that on contrast-enhanced computed tomography (CECT). 40 pathologically proven ICC lesions in 40 patients were evaluated retrospectively with both CEUS and CECT. The enhancement level and pattern in the dynamic phases on both CEUS and CECT were analysed. The diagnostic results of CEUS and CECT before pathological examination were also recorded. During arterial phases, the number of lesions that appeared as (i) peripheral irregular rim-like hyperenhancement, (ii) diffuse heterogeneous hyperenhancement, (iii) diffuse homogeneous hyperenhancement and (iv) diffuse heterogeneous hypoenhancement were 19 (47.5%), 9 (22.5%), 5 (12.5%) and 7 (17.5%), respectively, on CEUS, and 22 (55.0%), 3 (7.5%), 2 (5.0%) and 13 (32.5%), respectively, on CECT (p = 0.125). In the portal phase, the number of lesions showing hyperenhancement and hypoenhancement were 1 (2.5%) and ...
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target Academic Article ...
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma - Full Text View - ClinicalTrials.gov
The purpose of this project is to evaluate the role of gadoxetate (Eovist) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma, by exploiting the combination of the physiologic behavior of gadoxetate in liver tissue combined with the advantageous mass attenuation coefficient of Gadolinium achievable through dual energy technique. This combination of unique CT imaging sensitivity, high resolution and differential enhancement potentially allows improved visualization and detection of tumor relative to enhancing surrounding hepatic parenchyma and ductal anatomy in the hepatobiliary phase, due to the biliary excretion of the agent.. Cholangiocarcinoma is a hepatic adenocarcinoma that arises from the bile duct epithelium and is the second most prevalent liver cancer after hepatocellular carcinoma. The hilar intrahepatic variety of cholangiocarcinoma can present as an infiltrative, exophytic, or polypoid lesion. Most extra-hepatic cholangiocarcinomas are infiltrative, causing a ...
Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic...
OBJECTIVES: Hepatocellular carcinoma and cholangiocarcinoma form the majority of primary hepatic tumours and are the third most common cause of cancer-related deaths. These liver tumours rapidly outgrow their vascular supply and become hypoxic, resulting in the production of hypoxia inducible factors and triggering the angiogenic switch. Therefore, inhibiting angiogenesis has proven to be a valuable therapeutic strategy in hepatocellular carcinoma, yet less is known about its use in cholangiocarcinoma. In this study, we assess whether inhibiting the placental growth factor (PlGF) could offer a therapeutic option in mice with hepatocellular carcinoma and cholangiocarcinoma. PlGF is a homologue of the vascular endothelial growth factor, which is only involved in pathological angiogenesis, therefore, its inhibition does not induce adverse effects. METHODS: We have used a chemically induced transgenic mouse model in which both hepatocellular carcinoma and cholangiocarcinoma develop after 25 weeks ...
The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma<...
TY - JOUR. T1 - The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. AU - Zhang, Xu Feng. AU - Squires, Malcolm H.. AU - Bagante, Fabio. AU - Ethun, Cecilia G.. AU - Salem, Ahmed. AU - Weber, Sharon M.. AU - Tran, Thuy. AU - Poultsides, George. AU - Son, Andre Y.. AU - Hatzaras, Ioannis. AU - Jin, Linda. AU - Fields, Ryan C.. AU - Weiss, Matthew J. AU - Scoggins, Charles. AU - Martin, Robert C.G.. AU - Isom, Chelsea A.. AU - Idrees, Kamron. AU - Mogal, Harveshp D.. AU - Shen, Perry. AU - Maithel, Shishir K.. AU - Schmidt, Carl R.. AU - Pawlik, Timothy M.. PY - 2018/2/22. Y1 - 2018/2/22. N2 - Background: The impact of re-resection of a positive intraoperative bile duct margin on clinical outcomes for resectable hilar cholangiocarcinoma (HCCA) remains controversial. We sought to define the impact of re-resection of an initially positive frozen-section bile duct margin on outcomes of patients undergoing surgery for HCCA. ...
Identification of Cholangiocarcinoma by Using the Spyglass Spyscope System for Peroral Cholangioscopy and Biopsy Collection
Background and Aims: It is a challenge to collect samples from bile duct strictures to diagnose patients with cholangiocarcinoma. We investigated the utility of the Spyglass Spyscope, a single-operator endoscope that is used to perform cholangiopancreatoscopy, to identify extrahepatic cholangiocarcinoma in patients who were not diagnosed with this disorder by endoscopic retrograde cholangiopancreatography (ERCP) cytology or endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) analyses. Methods: We conducted a retrospective analysis of data from 30 patients (median age, 67 years; 67percent male) with indeterminate extrahepatic biliary strictures who were ultimately diagnosed with cholangiocarcinoma but had inconclusive results from initial biliary ductal brush cytology and EUS-FNA analyses. Patients then underwent cholangioscopy by using the Spyglass Spyscope and intraductal biopsy analysis. None of the patients had a definitive mass in abdominal imaging or EUS analyses. Results: The ...
Hepatitis C virus infection of cholangiocarcinoma cell lines. - NDM Research Building
Hepatitis C virus (HCV) infects the liver and hepatocytes are the major cell type supporting viral replication. Hepatocytes and cholangiocytes derive from a common hepatic progenitor cell that proliferates during inflammatory conditions, raising the possibility that cholangiocytes may support HCV replication and contribute to the hepatic reservoir. We screened cholangiocytes along with a panel of cholangiocarcinoma-derived cell lines for their ability to support HCV entry and replication. While primary cholangiocytes were refractory to infection and lacked expression of several entry factors, two cholangiocarcinoma lines, CC-LP-1 and Sk-ChA-1, supported efficient HCV entry; furthermore, Sk-ChA-1 cells supported full virus replication. In vivo cholangiocarcinomas expressed all of the essential HCV entry factors; however, cholangiocytes adjacent to the tumour and in normal tissue showed a similar pattern of receptor expression to ex vivo isolated cholangiocytes, lacking SR-BI expression, explaining their
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: A case-control study in...
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: A case-control study in Korea
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells...
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells Novel cancer therapy;TRAIL/Apo2L;non-conventional anti-cancer therapy;apoptosis; In the past decade, the incidence and mortality rates of cholangiocarcinoma (CCA) have been increasing worldwide. The relatively low responsiveness of CCA to conventional chemotherapy leads to poor overall survival. Recently, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL or Apo2L) has emerged as the most promising anti-cancer therapeutic agent since it is able to selectively induce apoptosis of tumor cells but not normal cells. In this study, we aimed to investigate the therapeutic effect of TRAIL in CCA cell lines (M213, M214 and KKU100) compared with the immortal biliary cell line, MMNK1, either alone or in combination with a subtoxic dose of 5-fluorouracil (5-FU). We found that recombinant human TRAIL (rhTRAIL) was a potential agent which significantly inhibited cell
ncRNAs in Exosomes of Cholangiocarcinoma - Full Text View - ClinicalTrials.gov
Exosomes are part of extracellular vesicles(EVs), and can be secreted into the environment by many types of cells. It has been demonstrated that the content and function of exosomes depends on the originating cell and the conditions under which they are produced.Exosomes contain proteins,RNAs and lipid,which may transfer biological information and activities from donor cells to receptor cells. Non-coding RNAs are involved in many biological activities including tumor growth and metastasis.. In this prospective translational study, preclinical and clinical phases have been designed. On the first step, the main goal is to characterize the ncRNAs of cholangiocarcinoma derived exosomes. This exosome biomarker may provide a useful diagnostic tool. As a second step, the study will evaluate the prognostic and predictive value of cholangiocarcinoma exosomes levels in plasma in a prospectively recruited cohort of cholangiocarcinoma patients before and after surgical resection. ...
Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma...
TY - JOUR. T1 - Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. AU - Techasen, Anchalee. AU - Namwat, Nisana. AU - Loilome, Watcharin. AU - Duangkumpha, Kassaporn. AU - Puapairoj, Anucha. AU - Saya, Hideyuki. AU - Yongvanit, Puangrat. PY - 2014/9. Y1 - 2014/9. N2 - Background The epithelial-mesenchymal transition (EMT) process strongly contributes to cancer metastasis. This study was to investigate the alteration of EMT-related proteins (ZEB1, ZEB2 and S100A4) in cholangiocarcinoma (CCA) tissues. The effect of tumor necrosis factor-α (TNF-α) on the expression of those molecules in CCA cells was investigated. Methods The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was used to quantify ZEB1, ZEB2 and S100A4 mRNA levels in 50 CCA tissues and related its expression to clinicopathological data. ZEB2 protein immunostaining was investigated in 165 CCA tissues. The effect of ...
ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018 - ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that it is an Oak sponsor of the Cholangiocarcinoma Foundation Annual Conference 2018 in Salt Lake City, Utah.. The conference is organised by the Cholangiocarcinoma Foundation and will be held from 31 January to 2 February 2018. Bringing together researchers, healthcare professionals, policymakers, patients and their caregivers, the conference encourages the engagement of the medical and research communities on cholangiocarcinoma by providing a forum for knowledge and innovation exchange.. For more information, please refer to the English or Chinese press release.. ...
Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine,...
Metastatic biliary tract cancer (BTC) has poor prognosis. Recently, patients with metastatic BTC who respond well to systemic chemotherapy can be treated by radical resection or
Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of...
Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant.
Combined portal vein resection for hilar cholangiocarcinoma. - Semantic Scholar
BACKGROUND Surgery is the only curative therapy for patients with hilar cholangiocarcinoma (HCCA). Combined portal vein resection (PVR) could achieve negative resection margins in HCCA patients with portal vein invasion. This systematic review aimed to analysis the efficiency of combined PVR for HCCA. METHODS MEDLINE, EMBASE, the Cochrane Library, the Chinese National Knowledge Infrastructure database, and clinical trial registries were searched through April 2015. Risk ratios (RRs), and 95% confidence intervals (CIs) were calculated. RESULTS The analysis included 21 retrospective studies, altogether involving 2403 patients (patients with PVR, n=637; patients without PVR, n=1766). Patients with PVR were likely to have more advanced HCCA (lymphatic invasion: RR=1.14, 95% CI 1.02 to 1.28; perineural invasion: RR=1.31, 95% CI 1.05 to 1.63) and suffered less curative resections (RR=0.89, 95% CI 0.75 to 0.99). Postoperative morbidity was similar between patients with or without PVR (RR=1.06, 95% CI 0.94
World Cholangiocarcinoma Day 2018 CCA: The facts
In the west, the exact cause of cholangiocarcinoma is unclear. It is likely that this cancer arises due to a combination of factors, including other illnesses that cause chronic damage to the liver and/or bile ducts, certain toxins and possibly a small genetic predisposition, although it is not believed to be a directly inherited disease. Although most cases of cholangiocarcinoma are in people over 60 years of age, it appears to be increasing across all age groups including younger people. The cause of this ongoing rise is currently unknown.. In Southeast Asia, especially Thailand, which has the worlds highest incidence of cholangiocarcinoma, associated risk factors include eating raw fish infected with liver fluke and chronic typhoid, neither of which occurs in the western world.. ...
Combined Portal Vein Resection for Hilar Cholangiocarcinoma: A Meta-analysis of Comparative Studies
Hilar cholangiocarcinoma (HCCA) frequently invades into the adjacent portal vein, and portal vein resection (PVR) is the only way to manage this condition and achieve negative resection margins. However, the safety and effectiveness of PVR is controversial. Studies analyzing the effect of PVR on the surgical and pathological outcomes in the management of HCCA with gross portal vein involvement were considered eligible for this meta-analysis. The outcome variables analyzed included postoperative morbidity, mortality, survival rate, proportion of R0 resection, lymph node metastasis, microscopic vascular invasion, and perineural invasion. From 11 studies, 371 patients who received PVR and 1,029 who did not were identified and analyzed. Data from patients who received combined PVR correlated with higher postoperative death rates (OR = 2.31; 95 % CI, 1.21-4.43; P = 0.01) and more advanced tumor stage. No significant difference was detected in terms of morbidity, proportion of R0 resection, or 5-year ...
Hepatolithiasis and Intrahepatic Cholangiocarcinoma: A Review - PubMed
Although the incidence of hepatolithiasis is decreasing as the pattern of gallstone disease changes in Asia, the prevalence of hepatolithiasis is persistently high, especially in Far Eastern countries. Hepatolithiasis is an established risk factor for cholangiocarcinoma (CCA), and chronic proliferat …
Best Cholangiocarcinoma Doctor in Kolkata, Cholangiocarcinoma Doctors | Credihealth
Find the best cholangiocarcinoma doctors in Kolkata. Get guidance from medical experts to select cholangiocarcinoma specialist in Kolkata from trusted hospitals - credihealth.com
Molecules and Cells
Cholangiocarcinoma is a malignant tumor that originates from the bile duct epithelium (Roberts et al., 1997). Based on its anatomical location in the biliary tree, cholangiocarcinoma is conventionally classified by the World Health Organization as an intrahepatic (ICC) or extrahepatic cholangiocarcinoma (ECC) (Bosman et al., 2010; Patel, 2011). ICC and ECC are biologically distinct, and therefore manifest substantial differences in terms of incidence, mortality, and risk factors (Cardinale et al., 2010). Cholangiocarcinoma has a poor prognosis because it is notoriously difficult to diagnose due to its late clinical presentation, and is refractory to conventional chemotherapy and radiation therapy (Blechacz and Gores, 2008; Blechacz et al., 2011; Khan et al., 2012). Gemcitabine and cisplatin has become the standard regimen for patients with advanced or metastatic cholangiocarcinoma (Ramirez-Merino et al., 2013; Valle et al., 2010). However, response to the combination chemotherapy in ...
Bile Duct Cancer (Cholangiocarcinoma) Resources - Navigating Care
What is Bile Duct Cancer (Cholangiocarcinoma)? Get the facts about Bile Duct Cancer (Cholangiocarcinoma) symptoms, testing, treatment and care options from trusted sources.
Calendar - Cholangiocarcinoma Foundation
TT-00420, a multi-target novel kinase inhibitor that can conveniently taken via once daily oral administration, has proven to be safe and well tolerated in the Phase I clinical study. In addition, TT-00420 has shown promising clinical benefit potential in adult patients with advanced cholangiocarcinoma who received TT-00420 at different dose levels ranged from 8 mg to 12 mg. In this webinar, Dr. Javle, a leading key opinion leader in cholangiocarcinoma innovative drug development, will review the two cases of advanced CCA patients who achieved partial responses in TT-00420 Phase I study. Dr. Javle will further share more scientific background about TT-00420, especially the tumor grown inhibition shown in nonclinical PDX study for CCA without FGFR alternations. TT-00420 is developed by TransThera Biosciences, who is dedicatedly working on the late phase development of TT-00420 in CCA in the U.S., so to offer more effective treatment options to CCA patients.. ...
Cholangiocarcinoma (CCA) is a highly lethal malignant tumor arising from the - nhibition of CXCR2 signaling promotes recovery
Cholangiocarcinoma (CCA) is a highly lethal malignant tumor arising from the biliary tract epithelium. that this Nes overexpression of IL-6 in CCA effectively suppresses the expression of miR-370 from your maternal allele, lending support to the theory that miR-370 silencing in human CCA follows a classic two-hit mechanism. Introduction Cholangiocarcinoma (CCA) is an Arry-380 aggressive tumor of the biliary tract . CCAs are usually diagnosed late in their progression, and the patient survival is usually measured in months . Molecular characterization of CCAs further suggested that inflammation and cholestasis, through modulation of genes involved in DNA damage repair, promote cancer development . IL-6 is usually a recognized mitogen and survival factor in human CCA and can contribute to tumor pathogenesis or progression . Therefore, it appears that elucidation of pathways downstream of IL-6 merits further investigation. DNA methylation refers to the addition of a methyl group to a ...
PRIME PubMed | Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis
PubMed journal article: Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis. Download Prime PubMed App to iPhone, iPad, or Android
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 : ReportsnReports
[504 Pages Report] Check for Discount on Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review,...
Radiological Imaging for Assessing the Respectability of Hilar Cholangiocarcinoma: A Systematic Review and Meta-Analysis
Hilar cholangiocarcinoma (HCC) remains one of the most difficult tumors to stage and treat. The aim of the study was to assess the diagnostic efficiency of computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computer tomography (PET/CT) in evaluating the resectability of HCC. A systematic search was performed of the PubMed, EMBASE, and Cochrane databases. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated for individual studies and pooled data as well as test for heterogeneity and public bias. Our data showed that CT had the highest pooled sensitivity at 95% (95% CI: 91–97), whereas PET/CT had the highest pooled specificity at 81% (95% CI: 69–90). The area under the curve (AUC) of CT, MRI, and PET/CT was 0.9269, 0.9194, and 0.9218, respectively. In conclusion, CT is the most frequently used imaging modality to assess HCC resectability with a good
Most recent papers with the keyword perihilar cholangiocarcinoma | Read by QxMD
Cholangiocarcinoma (CCA) is the second most common liver cancer and it is associated with a poor prognosis. CCA can be divided into intrahepatic, hilar and distal. Despite the subtype, the median survival is 12-24 months without treatment. Liver transplantation (LT) is worldwide recognized as a curative option for hepatocellular carcinoma. On the other hand, the initial results for LT for CCA were very poor mainly due to a lack of adequate patient selection. In the last two decades, improvement has been made in the management of unresectable hilar CCA, and the results of LT after neoadjuvant chemoradiation have been shown to be promising ...
Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma -...
Expression of MUC1 was detected immunohistochemically in 38 (76%) of 50 cases of m-ICC (ductal type, 18; cytoplasmic type, 20; and negative type, 12). Seventy-five percent of patients with lymph node metastasis had the cytoplasmic type MUC1 expression. Lymph node dissection was performed in only 20 patients, but significant correlation was demonstrated between MUC1 expression and lymph node metastasis (P = 0.0227). The location of MUC1 expression correlated with surgical outcome in m-ICC. Patients with the cytoplasmic type expression showed significantly lower survival rates. Univariate analysis revealed that MUC1 expression was a statistically significant risk factor affecting outcome in m-ICC (P = 0.0028). Furthermore, expression of MUC1 was found to be a statistically significant independent risk factor in multivariate analysis (P = 0.0063). ...
SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma<...
TY - JOUR. T1 - SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. AU - Merino-Azpitarte, Maite. AU - Lozano, Elisa. AU - Perugorria, María J.. AU - Esparza-Baquer, Aitor. AU - Erice, Oihane. AU - Santos-Laso, Álvaro. AU - ORourke, Colm J.. AU - Andersen, Jesper B.. AU - Jiménez-Agüero, Raúl. AU - Lacasta, Adelaida. AU - DAmato, Mauro. AU - Briz, Óscar. AU - Jalan-Sakrikar, Nidhi. AU - Huebert, Robert C.. AU - Thelen, Kristen M.. AU - Gradilone, Sergio A.. AU - Aransay, Ana M.. AU - Lavín, José L.. AU - Fernández-Barrena, Maite G.. AU - Matheu, Ander. AU - Marzioni, Marco. AU - Gores, Gregory J.. AU - Bujanda, Luis. AU - Marin, José J.G.. AU - Banales, Jesús M.. PY - 2017/7/1. Y1 - 2017/7/1. N2 - Background & Aims Cholangiocarcinoma (CCA) is a biliary malignancy linked to genetic and epigenetic abnormalities, such as hypermethylation of SOX17 promoter. Here, the role of SOX17 in cholangiocyte differentiation and ...
Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma?...
High-grade dysplasia/carcinoma in situ (HGD/CIS) of the biliary duct margin was found to not affect the prognosis of patients with extrahepatic cholangiocarcinoma by recent studies, but it has not yet reached a conclusion. Eligible studies were searched by PubMed, PMC, MedLine, Embase, the Cochrane Library, and Web of Science, from Jan. 1, 2000 to Jun. 30, 2019, investigating the influences of surgical margin status of biliary duct on the prognosis of patients with resectable extrahepatic cholangiocarcinoma. Overall survival (OS) and local recurrence were evaluated by odds ratio (OR) with 95% confidence interval (CI). A total of 11 studies were enrolled in this meta-analysis, including 1734 patients in the R0 group, 194 patients in the HGD/CIS group, and 229 patients in the invasive carcinoma (INV) group. The pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and R0 group was 0.98 (95% CI 0.65~1.50), 1.01 (95% CI 0.73~1.41), and 0.98 (95% CI 0.72~1.34), respectively. The pooled OR for
Rare Cancer News & Clinical Trials » Trials - Gall Bladder Cancer » August 19, 2017
Conditions: Extrahepatic Bile Duct Adenocarcinoma, Biliary Type; Gallbladder Adenocarcinoma, Biliary Type; Metastatic Pancreatic Adenocarcinoma; Recurrent Cholangiocarcinoma; Recurrent Gallbladder Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Intrahepatic Cholangiocarcinoma; Recurrent Pancreatic Carcinoma; Stage III Gallbladder Cancer AJCC V7; Stage III Hepatocellular Carcinoma AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage ...
Rare Cancer News & Clinical Trials » Trials - Gall Bladder Cancer
Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder ...
Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma<...
TY - JOUR. T1 - Surveillance of primary sclerosing cholangitis with ERC and brush cytology. T2 - risk factors for cholangiocarcinoma. AU - Boyd, Sonja. AU - Mustonen, Harri. AU - Tenca, Andrea. AU - Jokelainen, Kalle. AU - Arola, Johanna. AU - Färkkilä, Martti A.. PY - 2016/11/2. Y1 - 2016/11/2. N2 - Objective: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease leading to bile duct strictures and fibrosis, and predisposing to cholangiocarcinoma (CCA). Biliary dysplasia is a known precursor of CCA. In our unit, PSC patients undergo regular surveillance with ERC and brush cytology (BC), and liver transplantation is an option in case with biliary dysplasia. We evaluated the risk factors for biliary dysplasia and CCA based on ERC imaging, BC and liver function tests. Patients and methods: Seven hundred and eighty-eight ERCs were performed with BC for 447 PSC patients. ERC images were evaluated using the modified Amsterdam score, neutrophilic inflammation was assessed in ...
Cholangiocarcinoma Patient- Steve Holmes - One Year on Keytruda - Cholangiocarcinoma Australasia
Cholangiocarcinoma Patient - Steve Holmes One year on KeytrudaOne year to go. This one for my brother Graeme, another Cholangiocarcinoma WarriorGraeme Holmes RIP 2014 - Graeme you always had such canny luck, but it left you when you most needed it - I think it found me
Lymph Node Dissection Impact on Staging and Survival of Extrahepatic Cholangiocarcinomas, Based on U.S. Population Data |...
Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of extrahepatic CC and survival based on the SEER 1973-2004 database. Out of 20
Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma<...
TY - JOUR. T1 - Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. AU - Ailawadhi, Sikander. AU - Nagase, Hiroki. AU - Khoury, Thaer. AU - Yu, Jihnhee. AU - Tan, Dongfeng. AU - Black, Jennifer. AU - Brattain, Michael. AU - Javle, Milind. PY - 2007/7. Y1 - 2007/7. N2 - Background/Aims: The mucin-associated trefoil factor (TFF) peptides are integral to cytoprotection. TFF-3 is aberrantly expressed in colorectal and hepatocellular cancer and associated with an invasive phenotype. TFF-3 is also expressed in normal biliary epithelium. However, its role in biliary cancers is unknown. The biological effects of TFFs may result from EGFR, PI3 kinase, COX-2 and STAT-mediated signaling. We investigated the expression of TFF-3, Erk, Akt, EGFR and COX-2 in biliary cancer. Methodology: Twenty-four consecutive cases of cholangiocarcinoma treated from 1996-2002 were studied. Immunohistochemistry was performed using monoclonal antibodies to TFF-3, EGFR, ...
Bile Duct Cancer Prognosis
Cholangiocarcinoma (bile duct cancer) usually develops in the bile duct system that arises from the liver and bile ducts and ends at the small intestine. Cancer that develops in the section of bile ducts within and outside the liver is called as intrahepatic and hilar cholangiocarcinoma, respectively. Distal cholangiocarcinoma is developed in the bile section that is associated with small intestine. Prognostic factors of cholangiocarcinoma are highly disputable.
As a Cholangiocarcinoma patient living in Australia - Cholangiocarcinoma Australasia
Foreword by Steve This is a good video clip that gives insight into the future direction of immunotherapy. As a Cholangiocarcinoma patient living in Australia and trying to understand the what, how and where tos of this immunotherapy wave is vitally important to my decision making.
Aging | Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition...
Background: Cholangiocarcinoma (CCA) is a serious malignant tumor. Long non-coding RNA NNT-AS1 (NNT-AS1) takes crucial roles in several tumors. So, we planned to research the roles and underlying mechanism of NNT-AS1 in CCA.Results: NNT-AS1 overexpression was appeared in CCA tissues and cell lines. Proliferation was promoted by NNT-AS1 overexpression in CCLP1 and TFK1 cells. Besides, NNT-AS1 overexpression reduced E-cadherin level and raised levels of N-cadherin, vimentin, Snail and Slug. However, the opposite trend was occurred by NNT-AS1 knockdown. Further, NNT-AS1 overexpression promoted phosphatidylinositol 3 kinase (PI3K)/AKT and extracellular signal-regulated kinase (ERK)1/2 pathways. MiR-203 was sponged by NNT-AS1 and miR-203 mimic reversed the above promoting effects of NNT-AS1. Additionally, insulin-like growth factor type 1 receptor (IGF1R) and zinc finger E-box binding homeobox 1 (ZEB1) were two potential targets of miR-203.Conclusion: NNT-AS1 promoted proliferation, EMT and PI3K/AKT and ERK1
Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma - Zurich Open Repository and Archive
Cholangiocarcinoma (CCA) cells paradoxically express the death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and thus rely on potent survival signals to circumvent cell death by TRAIL. Hedgehog (Hh) signaling is an important survival pathway in CCA. Herein, we further examine the mechanisms whereby Hh signaling mediates apoptosis resistance in CCA, revealing a pivotal role for the cell division regulating serine/threonine kinase polo-like kinase 2 (PLK2). We employed 50 human CCA samples (25 intrahepatic and 25 extrahepatic CCA) as well as human KMCH-1, Mz-CHA-1, and HUCCT-1 CCA cells for these studies. In vivo experiments were conducted using a syngeneic rat orthotopic CCA model. In human samples, polo-like kinase (PLK)1/2/3-immunoreactive cancer cells were present in the preponderance of intra- and extrahepatic CCA specimens. Inhibition of Hh signaling by cyclopamine reduced PLK2, but not PLK1 or PLK3, messenger RNA and protein expression in vehicle-treated and sonic ...
Researchers Hope to Individualize Cancer Treatment With Liquid Biopsy | Discoverys Edge
Researchers are exploring how broadly liquid biopsies might be used. In the Journal of Clinical Oncology: Precision Oncology, a Mayo Clinic research team reported the array of cancer-related genetic mutations present in liquid biopsies of bile duct cancer, a form of liver cancer also known as cholangiocarcinoma. We charted the landscape of genetic alterations present in circulating tumor DNA among patients with cholangiocarcinoma, explains Dr. Mody, the articles lead author. The team evaluated liquid biopsies in one of the largest patient cohorts to date: 124 patients with cholangiocarcinoma who were treated across Mayos three campuses. Our findings provide a foundation for further development of liquid biopsies as a way to advance precision medicine for patients with cholangiocarcinoma, he says.. Cholangiocarcinoma is uncommon in the U.S., where about 5,000 new cases are diagnosed each year, though numbers have been on the rise in recent decades. The cancer is more prevalent in Southeast ...
Bile Duct Cancer (Cholangiocarcinoma) Treatment (PDQ®): Treatment - Health Professional Information [NCI] | PeaceHealth
Cancer of the bile duct (also called cholangiocarcinoma) is extremely rare. The true incidence of bile duct cancer is unknown, however, because establishing an accurate diagnosis is difficult. Traditionally, bile duct tumors located within the liver have been classified with hepatocellular carcinoma as primary liver...
Biomarkers of Opisthorchis viverrini-induced cholangiocarcinoma - Paul Brindley
Cholangiocarcinoma (CCA) - bile duct cancer - is associated with late presentation, poses challenges for diagnosis and has high mortality, features that highlig...
Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger...
Aims: To compare the long-term prognosis of younger and elderly patients with combined hepatocellular-cholangiocarcinoma (CHC) who underwent curative resection between 1993 and 2014 at our center.. Methods: Two hundred and thirteen patients who underwent liver resection for CHC were enrolled in our study. The overall survival (OS) and disease-free survival (DFS) of elderly patients (age≥60, n=52) and younger patients (age,60, n=161) were compared by multivariate analysis and propensity score matching (PSM) analysis.. Results: Among the 213 CHC patients, the elderly patients had a higher rate of worse Child-Pugh grade (P=0.027), abnormal serum albumin (P,0.001) and lymphoid metastases (P=0.024). The proportion of HBV-positive CHC patients (74.6%, 159/213) was much higher than that observed in healthy cohorts. Younger patients had a higher rate of hepatitis B virus (HBV) infection compared to older patients (83.9% vs 46.2%, P,0.001). OS and DFS of the elderly and younger patients before and ...
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation
Biliary tract cancers (BTC) comprise a group of rare and heterogeneous poor-prognosis tumours with the incidence of intrahepatic cholangiocarcinoma increasing over recent years. Combination chemotherapy with gemcitabine and cisplatin is the established first-line treatment for advanced BTC with a significant but modest survival advantage over monotherapy. There remains no accepted standard treatment in the second-line setting, although recent results from a randomised study have shown a survival benefit with 5-fluorouracil and oxaliplatin chemotherapy. Historically, clinical trials investigating targeted therapies in unselected BTC have failed to demonstrate significant clinical benefit. More recently, advancement in molecular exploration of BTC has shed light on the complex biological heterogeneity within these tumours and has also identified actionable genomic aberrations, such as fibroblast growth factor receptor 2 (FGFR2) gene fusions, isocitrate dehydrogenase (IDH) and BRAF mutations, which ...
Cholangiocarcinoma: Practice Essentials, Pathophysiology, Epidemiology
Cholangiocarcinomas (CCCs) are malignancies of the biliary duct system that may originate in the liver and extrahepatic bile ducts, which terminate at the ampulla of Vater. CCCs are encountered in three anatomic regions: intrahepatic, extrahepatic (ie, perihilar), and distal extrahepatic.
Maffucci syndrome and neoplasms: a case report and review of the literature | BMC Research Notes | Full Text
Maffucci syndrome is characterized by the sporadic occurrence of multiple enchondromas together with multiple hemangiomas. Patients with Maffucci syndrome are at increased risk of developing different kinds of malignant tumors. We report on a 39-year-old woman who was diagnosed with Maffucci syndrome together with intrahepatic cholangiocarcinoma (IHCC). Heterozygous somatic mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/IDH2) genes are associated with a number of different tumor types (e.g. IHCC) and also with Maffucci syndrome. For IHCC, mutations in IDH1/IDH2 are associated with higher survival rates. IHCC tissue as well as normal liver tissue and peripheral blood were analyzed for IDH1/IDH2-mutations in our patient. In the tumor sample, we identified a recurrent somatic IDH1-mutation affecting Arg132, while in normal liver tissue and peripheral blood, no variants were detected, as expected. This case report presents the second patient in the literature exhibiting the features of Maffucci
RePub, Erasmus University Repository: The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic...
Background: The objective of the current study was to assess the impact of serum CA19-9 and CEA and their combination on survival among patients undergoing surgery for intrahepatic cholangiocarcinoma (ICC). Methods: Patients who underwent curative-intent resection of ICC between 1990 and 2016 were identified using a multi-institutional database. Patients were categorized into four groups based on combinations of serum CA19-9 and CEA (low vs. high). Factors associated with 1-year mortality after hepatectomy were examined. Results: Among 588 patients, 5-year OS was considerably better among patients with low CA19-9/low CEA (54.5%) compared with low CA19-9/high CEA (14.6%), high CA19-9/low CEA (10.0%), or high CA19-9/high CEA (0%) (P , 0.001). No difference in 1-year OS existed between patients who had either high CA19-9 (high CA19-9/low CEA: 70.4%) or high CEA levels (low CA19-9/high CEA: 72.5%) (P = 0.92). Although patients with the most favorable tumor marker profile (low CA19-9/low CEA) had the ...
The precancerous liver; correlations of histological and biochemical changes in rats during prolonged administration of...
Though much is known about the pathology of the rats liver during chemical carcinogenesis, and the associated biochemical changes have been studied extensively with some compounds, especially 4-dimethylaminoazobenzene (DAB, butter yellow), hardly any attempt has been made to follow such changes progressively or to correlate them with the histological findings. Malignant tumours of the liver are roughly divisible into cancers of the bile duct cells (cholangiocarcinomas) and those of the liver cells (hepatomas). In our experiments cholangiocarcinomas were produced by feeding thioacetamide or DAB, whereas hepatomas resulted if DAB with a vitamin B-rich diet was used. The events which decide the type of tumour which develops may be summarized thus: a cholangiocarcinoma occurs when the following changes are found in the liver, damage to parenchymal cells, proliferation of bile duct tissue, a drop in the mitochondrial fraction, and the phenomenon of ageing of mitochondria. During this time there ...
Bile Duct Cancer (Cholangiocarcinoma)
Bile duct cancer symptoms include jaundice and abdominal pain. Turn to the expert gastroenterologists at Johns Hopkins for accurate diagnosis and personalized treatment.
Bile Duct Cancer | Cholangiocarcinoma - Glossary
Looking for simple explanations to difficult medical terms that tend to puzzle you? This glossary can help you to easily understand medical terms related to the article on Bile Duct Cancer
Dhanpat Jain, MD > Liver Center | Yale School of...
Liver tumors: One of the major areas of my research interest liver tumors. Some of the studies have been collaborative efforts with other academic Institutions in the country, while some have been my own. We have evaluated various markers that can be applied in the diagnostic work-up of hepatocytic masses, including hepatocellular carcinoma (HCC), hepatic adenoma (HA) and focal nodular hyperplasia (FNH) over the years. Our ongoing research in this area is looking at new markers and their diagnostic utility in the work-up of hepatic masses. We are also studying the HCCs that arise in patients with cirrhosis and chronic liver disorders and compare them with those without cirrhosis and known liver disease.. One of my major areas of research interest in liver tumors is Cholangiocarcinoma (CC). It is the second most common primary malignant neoplasm of the liver. The precursor lesions of cholangiocarcinoma are not well understood. Based on observations from clinical cases, we suspect that many of ...
Cholangiocarcinoma (bile duct cancer) - Doctors and departments - Mayo Clinic
Learn about symptoms, risk factors, diagnosis and treatment, including transplant, for this rare cancer that affects the bile ducts of older adults.
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic...
Evidence-based recommendations on endoscopic bipolar radiofrequency ablation for biliary obstruction caused by bile duct and pancreas cancers..
Heterologous Expression and Purification of Full-Length Human Polybrom by Sarah Hopson
Over the past decade, it has become apparent that the human polybromo-1 protein (BAF180) has a critical role in cancer. BAF180 is known to be a driver mutation in clear cell renal cell carcinoma, where it has been found to be mutated in approximately 40% of cases. Mutations have also been found in several other cancers, including intrahepatic cholangiocarcinomas and epithelioid sarcomas. BAF180 is the chromatin targeting subunit of the PBAF (Polybromo-associated BRG1-associated factor) chromatin remodeling complex, a role facilitated by its nine domains: six bromodomains, which recognize and bind to acetylated lysines on histones; two BAH (bromo-adjacent homology) domains, found to be critical for PCNA ubiquitination following DNA damage; and one HMG (high mobility group) box, the DNA binding component. Furthermore, proper expression of BAF180 has also been linked to cardiac development and cell cycle regulation. Despite these associations, the molecular level interactions of full-length BAF180 have yet
Publications - The Wood Laboratory
Exome sequencing reveals frequent inactivating mutations in BAP1, ARID1A, and PBRM1 in intrahepatic cholangiocarcinomas. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJA, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, TortoraG, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Nat Genet. 2013 Dec; 45(12):1470-3 ...
00008118 | PEIR Digital Library
HISTOLOGY: HEPATOBILIARY: LIVER: BILIARY: Cholangiocarcinoma: Micro high mag H&E growth along wall of portal vein not too sure that this case would be called cholangiocarcinoma today more like a hepatoma see also. ...
My Mum Mags - Page 2 - Cholangiocarcinoma Foundation Discussion Board
Dear All. Just updating on Mum.. We have had a bit of a rollercoaster over the last few months.. Mum was started on FOLFOX back in June…after having completed 11 Cycles of GEM/CIS. GEM/CIS was well tolerated.. FOLFOX was not so well tolerated and following two cycles was suspended by Mums oncologist. Main problem was tummy pains/some ascites. Not sure, however, whether the tummy pains were the chemo or the anti-sickness drugs.. Bone mets continue to wreak pain and we were fire fighting with radiotherapy. Then two weekends ago Mum woke up to such pain in her cervical vertebrae that we had to have her hospitalised. We thought she had fractured her neck or it was spinal cord compression. AN MRI confirmed it was just bone mets. She was discharged from hospital 3 days later with a new medication list, and a prescription for five fractions of radiotherapy to the cervical vertebrae area.. We followed the new pain medication list (which caused periodic wipe out for Mum) because it included diazepam ...
Holger Willenbring, MD, PhD | UCSF Helen Diller Family Comprehensive Cancer Center
Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827 ...
Cathy Sorenson (The Journey Through Cholangiocarcinoma)
Catherine Jane Midgley Sorenson, 1949 - 2011. On December 31, 2011, Cathys courageous fight with cancer ended and she returned home to her Heavenly Father. Cathy was born March 23, 1949 in Salt Lake City, Utah to Frank Park and Nedra Midgley, the sixth of eight children. From an early age, Cathy had a special relationship with her parents and valued family. Some of her fondest childhood memories were visiting her grandparents in California and their visits to Utah. In 1967, Cathy graduated from East High School in Salt Lake City. After some schooling in Chicago, she returned to Salt Lake where she continued to work until she met Jay Parson Sorenson. She and Jay were married on May 20, 1977 and he has been her eternal companion since that time. Cathy and Jay quickly started a family and are parents to five children. Her family, including her husband, five children, their spouses, and her eight grandchildren were the center of her life as she was an amazing wife, mom, grandmother, sister, aunt, ...
Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between...
Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct epithelial cell lining. The misdiagnosis of CCA and other biliary diseases may occur due to the similarity of clinical manifestations and blood tests resulting in inappropriate or delayed treatment. Thus, an accurate and less-invasive method for differentiating CCA from other biliary diseases is inevitable. We quantified methylation of OPCML, HOXA9, and HOXD9 in serum cell-free DNA (cfDNA) of CCA patients and other biliary diseases using methylation-sensitive high-resolution melting (MS-HRM). Their potency as differential biomarkers between CCA and other biliary diseases was also evaluated by using receiver operating characteristic (ROC) curves. The significant difference of methylation levels of OPCML and HOXD9 was observed in serum cfDNA of CCA compared to other biliary diseases. Assessment of serum cfDNA methylation of OPCML and HOXD9 as differential biomarkers of CCA and other biliary diseases showed the area under curve (AUC) of 0.850 (0
What Is Perihilar Scarring of the Lungs?
Lung scarring can be a highly dangerous condition and is usually caused by inhaling dangerous chemicals or by infections. Lung scarring is generally defined by which area of the lung is injured, with the perihilar area, which is the major entrance for the major veins and arteries of the lungs, being the most common.
Advanced Imaging in Diagnosis and Treatment of Biliary Cancer | Memorial Sloan Kettering Cancer Center
Researchers in radiology at Memorial Sloan Kettering continue to assess multiple imaging methods in the quest to improve treatment options and success rates for patients with biliary cancers such as cholangiocarcinoma.
Bile Duct Cancer and Potential Risk Factor-Bacteria | DrStegall.com
Dr. Stegalls Comments: There are many theories as to how cancer develops, and one of them is that cancer starts as a bacteria. The idea that bacteria could cause cholangiocarcinoma is an interesting one, as it would suggest a possible target for treatment using off-label antibiotic regimens. I typically include a low dose antibiotic given intravenously in periodic fashion as part of my treatment protocols, in case there is a bacterial component ...
Cell lines and human tissue samples. Cell lines from four human pancreatic carcinomas (SU8686, AsPC1, BxPC3, and CFPAC1), two gastric cancers (AGS and MKN7), three hepatic carcinomas (Alexander, Hep3B, and HepG2), a cholangiocarcinoma (HuCCT), and embryonic kidney (HEK293T) were purchased from the American Type Culture Collection (Manassas, VA) or the Japanese Riken Cell Bank (Tsukuba, Japan). Normal hepatocytes were purchased from Dainippon Pharma (Osaka, Japan) and normal diploid colonocytes (CCD841) were purchased from American Type Culture Collection. Tissue specimens obtained during surgery or endoscopic resection were obtained from the University of Tokyo Hospital (Tokyo, Japan) and Motojima Memorial Hospital (Gumma, Japan) after approval from the medical ethics committee and the acquisition of informed consent. Some samples of colonic cancer and surrounding precancerous tissue were collected from identical specimens. Formalin-fixed, paraffin-embedded sections were examined by H&E staining ...
In cases of biliary stasis, detoxification can be problematic for the client and the therapist, so improving biliary flow should be a consideration. Biliary tract disease is on the increase with cholangiocarcinoma occurring in 65% of cases with recurring symptoms from gallstones in the over-65s. Patients who fall into the fair, fat, forty and fertile category are also at increased risk. Alteration ...
Search Clinical Trials | Vanderbilt-Ingram Cancer Center
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. Patients will receive anetumab ravtansine every three weeks in monotherapy for most indications. In cholangiocarinoma and adenocarinoma of the pancreas, 3-weekly anetumab ravtansine is administered in combination with cisplatin or gemcitabine respectively (both administered in a 2 week on / 1 week off schedule). Treatment will continue until disease progression or until another ...
Doxorubicin | Springer for Research & Development
Venturini M, et al. Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: A preliminary study. British Journal of Radiology 89: 20160247, No. 1067, Nov 2016. Available from: URL: http://doi.org/10.1259/bjr.20160247 - Italy ...
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with metastatic cholangiocarcinoma contained CD4+ T helper 1 (T(H)1) cells rec …
Wikimedia Commons has media related to Cholangiocarcinoma. Scholia has a topic profile for Cholangiocarcinoma. American Cancer ... Cancer.Net: Bile Duct Cancer Cholangiocarcinoma Foundation World Cholangiocarcinoma Day (CS1 German-language sources (de), ... A cholangiocarcinoma occurring at the junction where the left and right hepatic ducts meet to form the common hepatic duct may ... Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of ...
A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree) occurring at the confluence ... Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004). "Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison ... Cholangiocarcinoma accounts for approximately 2% of all cancer diagnoses, with an overall incidence of 1.2/100,000 individuals ... Acalovschi M (2004). "Cholangiocarcinoma: risk factors, diagnosis and management". Romanian Journal of Internal Medicine. 42 (1 ...
In 2007, Michael died of cholangiocarcinoma; Craighead was one of the founders of the Cholangiocarcinoma ... "Board of Directors". Cholangiocarcinoma Foundation. Retrieved March 3, 2015. "Joni Craighead to Run for Nebraska Legislature, ...
For instance, cholangiocarcinoma represents 15% of primary liver cancer worldwide, but in Thailand's Khon Kaen province, this ... Cholangiocarcinoma is typically incurable at diagnosis. Because of this, intervention strategies are focused on the prevention ... "Bile Duct Cancer (Cholangiocarcinoma) Treatment". National Cancer Institute. 23 September 2020. Retrieved 29 May 2021. Head, ... Of all cancers recorded worldwide in 2002, 0.02% were cholangiocarcinoma caused by Opisthorchis viverrini. Cancer of the bile ...
O. viverrini infection also increases the risk of cholangiocarcinoma, a cancer of the bile ducts. A small, leaf-like fluke, O. ... In rare cases, cholangitis, cholecystitis, and cholangiocarcinoma can also develop. In humans,O. viverrini inhabits mainly the ... cholangiocarcinoma (CCA) in the world. About 9.6% of the total population of Thailand is estimated to be infected. It is most ... "Liver fluke induces cholangiocarcinoma". PLOS Medicine. 4 (7): e201. doi:10.1371/journal.pmed.0040201. PMC 1913093. PMID ...
Rustagi T, Dasanu CA (June 2012). "Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and ... July 2007). "Liver fluke induces cholangiocarcinoma". PLOS Medicine. 4 (7): e201. doi:10.1371/journal.pmed.0040201. PMC 1913093 ...
It is believed to be a cause of cholangiocarcinoma via liver fluke transmission. Koi hoi is a dish containing raw snail meat ... "Liver Fluke Induces Cholangiocarcinoma". PLOS Medicine. 4 (7): e201. doi:10.1371/journal.pmed.0040201. PMC 1913093. PMID ...
Resection is an option in cholangiocarcinoma, but fewer than 30% of cases of cholangiocarcinoma are resectable at diagnosis. ... According to the United States National Cancer Institute, the incidence of cholangiocarcinoma is not known. Cholangiocarcinoma ... 60% of cholangiocarcinomas form in the perihilar region and photodynamic therapy can be used to improve quality of life and ... Intrahepatic cholangiocarcinoma (CCA) is an epithelial cancer of the intra-hepatic biliary tree branches. Intrahepatic CCA is ...
It is commonly used off-label to treat cholangiocarcinoma and other biliary tract cancers. It is given by intravenous infusion ... Plentz RR, Malek NP (December 2016). "Systemic Therapy of Cholangiocarcinoma". Visceral Medicine. 32 (6): 427-430. doi:10.1159/ ...
Alcohol and cancer
Ben-Menachem T (August 2007). "Risk factors for cholangiocarcinoma". Eur J Gastroenterol Hepatol. 19 (8): 615-7. doi:10.1097/ ...
Infection with the parasite, called opisthorchiasis is the major cause of cholangiocarcinoma, a cancer of the bile ducts, in ... Heavy infection with the trematode Platynosomum fastosum is associated with cholangiocarcinoma in cats. Cryptosporidium parvum ... 2007). "Liver Fluke Induces Cholangiocarcinoma". PLOS Medicine. 4 (7): e201. doi:10.1371/journal.pmed.0040201. PMC 1913093. ... 2017). "Opisthorchis felineus infection and cholangiocarcinoma in the Russian Federation: A review of medical statistics". ...
Development of cholangiocarcinoma is progressive. Infection is detected mainly on identification of eggs by microscopic ... A full 5% of chronic infections go on to develop cholangiocarcinoma. Drugs used to treat infestation include triclabendazole, ... and sometimes even cholangiocarcinoma, the incidence of which is raised in fluke-infested areas. One adverse effect of ... cholangiocarcinoma, and hepatic carcinoma. As a major causative agent of bile duct cancer, the International Agency for ...
High levels of alpha-fetoprotein (AFP) in the blood can be found in many cases of HCC and intrahepatic cholangiocarcinoma. ... Cholangiocarcinoma can be detected with these commonly used tumor markers: carbohydrate antigen 19-9 (CA 19-9), ... Other forms of primary forms of liver cancer include cholangiocarcinoma, mixed tumors, sarcoma, and hepatoblastoma. Upon ... "Serum markers of intrahepatic cholangiocarcinoma". Disease Markers. 34 (4): 219-28. doi:10.1155/2013/196412. PMC 3809974. PMID ...
Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells (or cells showing ... Cholangiocarcinoma is considered to be an incurable and rapidly lethal cancer unless both the primary tumor and any metastases ... The Cholangiocarcinoma Foundation The Johns Hopkins Gall Bladder & Bile Duct Cancer Web page Bile+Ducts at the US National ... cholangiocarcinoma, cancer of the bile ducts; blockage by a stone in patients with gallstones; and from scarring after injury ...
Deaths in October 2000
Thomas Gifford, 63, American author, cholangiocarcinoma. Ring Lardner Jr., 85, American journalist and screenwriter, cancer. ...
"Cholangioscopy-assisted photodynamic therapy for cholangiocarcinoma". Gastrointestinal Endoscopy. 81 (4): 1012-1013. doi: ...
Deaths in November 2013
Peter Wintonick, 60, Canadian documentary filmmaker, cholangiocarcinoma. Babe Birrer, 85, American baseball player (Detroit ...
Integrated Opisthorchiasis Control Program
"World Cholangiocarcinoma Day 2018 CCA: The statistics". worldcholangiocarcinomaday.org. Retrieved 25 January 2018. Sripa, ...
Deaths in November 1999
Walter Payton, 45, American football player, cholangiocarcinoma. William van Straubenzee, 75, British politician. Jackie Davis ...
Deaths in October 2009
Halit Refiğ, 75, Turkish film director, cholangiocarcinoma. Samy Abu Zaid, 30, Egyptian footballer, car accident. Maurice Agis ...
Cancers of the biliary tree, including cholangiocarcinoma. Colorectal cancer is a disease of old age: It typically originates ...
Cholangiocarcinoma is a rare form of cancer that forms in bile ducts, which are slender tubes that carry the digestive fluid ... "FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts". U.S. Food and Drug ... Pemigatinib is indicated for the treatment of adults with bile duct cancer (cholangiocarcinoma) that is locally advanced (when ... Pemigatinib is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast ...
Cholangiocarcinoma, or cancer of the bile duct, is an indication for the Whipple procedure when the cancer is present in the ... Depending on the location and extension of the cholangiocarcinoma, curative surgical resection may require hepatectomy, or ... "Advances in the surgical treatment of hilar cholangiocarcinoma". Expert Review of Gastroenterology & Hepatology. 9 (3): 369-374 ...
"Autoimmune pancreatitis associated with retroperitoneal fibrosis mimicking cholangiocarcinoma". Oxford Medical Case Reports. ...
Another primary malignant liver tumor is the cholangiocarcinoma. Hepatectomy may also be the procedure of choice to treat ...
He died of cholangiocarcinoma on 18 June 2018. He is survived by his wife, Dr Madhu Dixit Devkota, and three daughters. British ... Deaths from cholangiocarcinoma, Khas people, All stub articles, Medical biography stubs). ...
"FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma". U.S. Food and Drug Administration (FDA). 26 August 2021 ... Ivosidenib is indicated for people with acute myeloid leukemia and locally advanced or metastatic cholangiocarcinoma. In ... In tumors from people diagnosed with glioma, acute myeloid leukemia (AML), cholangiocarcinoma, and chondrosarcoma, somatic ... and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several ...
Deaths in December 1991
Gordon Pirie, 60, English Olympic runner (1956), cholangiocarcinoma. Francisco de Assis Barbosa, 77, Brazilian essayist, ...
Mir-26 microRNA precursor family
Human cholangiocarcinoma miR-26a promotes cholangiocarcinoma growth by inhibition of GSK-3β and subsequent activation of β- ... Human cholangiocarcinoma tissues and cell lines have increased levels of miR-26a compared with the noncancerous biliary ... On the contrary, miR-26a is overexpressed in high-grade glioma and cholangiocarcinoma. Elevated expression of miR-26b has been ... Overexpression of miR-26a by cholangiocarcinoma cells increases tumor growth in severe combined immune-deficient mice. GSK-3β ...
Deaths in May 2010
Ernie Harwell, 92, American baseball sportscaster (Detroit Tigers), cholangiocarcinoma. Peter Heathfield, 81, British trade ...
Cholangiocarcinoma: MedlinePlus Genetics
Cholangiocarcinoma is a group of cancers that begin in the bile ducts. Explore symptoms, inheritance, genetics of this ... cholangiocarcinoma.. The three types of cholangiocarcinoma do not usually cause any symptoms in their early stages, and this ... Cholangiocarcinoma is classified by its location in relation to the liver. Intrahepatic. cholangiocarcinoma begins in the small ... Cholangiocarcinoma is not inherited. Studies suggest that blood relatives of a person with cholangiocarcinoma may have an ...
Adjuvant Chemotherapy for Resectable Cholangiocarcinoma
Is adjuvant chemotherapy effective in patients with resectable cholangiocarcinoma, and does it prolong survival time? This new ... Table 1. Baseline characteristics and tumor data of the resectable cholangiocarcinoma patients, according to treatment group ... Adjuvant Chemotherapy in Resectable Cholangiocarcinoma Patients. Kosin Wirasorn; Thundon Ngamprasertchai; Narong Khuntikeo; Ake ... A retrospective study was conducted among newly diagnosed cholangiocarcinoma cancer patients, who underwent curative resection ...
Cholangiocarcinoma: Early Diagnosis Is Key
Cholangiocarcinoma is a relatively rare adenocarcinoma of the bile ducts that is rapidly fatal unless it can be completely ... In part to advance research on and treatment of cholangiocarcinoma, Dr. Kerr and Professor Vinod Raina, from the All India ... Medscape: What is the standard of care for operable cholangiocarcinoma? Dr. Kerr: Ideally, best care would include rapid ... Kerr discussed with Medscape current issues in the diagnosis and management of cholangiocarcinoma. ...
Phase II trial of docetaxel for cholangiocarcinoma
Seventeen patients with cytologically or histologically confirmed cholangiocarcinoma received intravenous docetaxel over 1 hour ... activity and toxicity of docetaxel given as a 1-hour infusion every 21 days in patients with unresectable cholangiocarcinoma. ... Phase II trial of docetaxel for cholangiocarcinoma Am J Clin Oncol. 1999 Feb;22(1):78-81. doi: 10.1097/00000421-199902000-00019 ... Administered on this dose and schedule, docetaxel lacked activity in patients with cholangiocarcinoma. The toxicity profile, ...
... CholangiocarcinomaClassification & external resources Digestive system diagram showing bile duct location ... Age-standardized mortality rates from intrahepatic (IC) and extrahepatic (EC) cholangiocarcinoma for men and women, by country ... Cholangiocarcinoma is a cancer of the bile ducts, which drain bile from the liver into the small intestine. It is a relatively ... A cholangiocarcinoma occurring at the junction where the left and right hepatic ducts meet to form the common bile duct may be ...
Cholangiocarcinoma Imaging: Practice Essentials, Computed Tomography, Magnetic Resonance Imaging
Cholangiocarcinoma is a slow-growing malignancy of the bile duct. It is the second most common primary hepatic tumor after ... Does intrahepatic cholangiocarcinoma have better prognosis compared to perihilar cholangiocarcinoma?. J Surg Oncol. 2010 Feb 1 ... encoded search term (Cholangiocarcinoma Imaging) and Cholangiocarcinoma Imaging What to Read Next on Medscape ... What are the imaging criteria for assessing local invasion of cholangiocarcinoma?. How is metastatic cholangiocarcinoma ...
cholangiocarcinoma | Gut
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions Rocio I R Macias, Vincenzo ... Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma Shuichi Aoki, ... Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications Miguel A Martin- ... GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic ...
Cholangiocarcinoma | Liver Cancer | UPMC Center for Liver Diseases
Cholangiocarcinoma is a rare cancer affecting the bile ducts inside and outside the liver. Learn how we treat bile duct cancer ... Distal cholangiocarcinoma. This cancer forms in bile ducts outside the liver. Intrahepatic cholangiocarcinoma is cancer that ... Bile Duct Cancer (Cholangiocarcinoma). Contact the UPMC Center for Liver Diseases. To make an appointment with a hepatologist ... Perihilar cholangiocarcinoma, or Klatskin tumor. This cancer forms in the hilum, the place where bile ducts merge when leaving ...
... also known as bile duct cancer commonly be found in people 50 years old and above. This type of cancer ... Hilar cholangiocarcinoma. This type is found outside the liver and also called perihilar cholangiocarcinoma or Klatskin tumor. ... Cholangiocarcinoma occurs when there is a change of DNA in the bile ducts. The DNA in the cells alters the cells behavior. ... Cholangiocarcinoma also known as bile duct cancer commonly be found in people 50 years old and above. This type of cancer ...
Bile Duct Cancer (Cholangiocarcinoma) Treated at Karmanos
Bile Duct Cancer (Cholangiocarcinoma) Treatment Near You. Use current location Zip code. ... Bile Duct Cancer (Cholangiocarcinoma) menu. Whats On This Page *Multidisciplinary Team. *Karmanos Bile Duct Cancer ( ... Bile Duct Cancer (Cholangiocarcinoma) Diagnostics and Treatment. When it comes to world-class cancer care close to home, look ... Treatment of Bile Duct Cancer (Cholangiocarcinoma). Information from the National Cancer Institute What is bile duct cancer?. ...
Calendar - Cholangiocarcinoma Foundation
Biliary Drainage Plus HAIC in Locally Advanced pCCA | Clinical Research Trial Listing ( Perihilar Cholangiocarcinoma ) (...
Clinical trial for Perihilar Cholangiocarcinoma , Biliary Drainage Plus HAIC in Locally Advanced pCCA ... Locally advanced perihilar cholangiocarcinoma proved by histology or cytology. Yes for Locally advanced perihilar ... Not sure for Locally advanced perihilar cholangiocarcinoma proved by histology or cytology inclusion criteria 1 ... No for Locally advanced perihilar cholangiocarcinoma proved by histology or cytology inclusion criteria 1 ...
Cholangiocarcinoma Foundation Archives - Utah Stories
Loving Parents Plan a 15,000 Mile Journey of Hope in Honor of Their Daughter that Passed Away from Cholangiocarcinoma. May 14, ... They plan to kick off their road trip in SLC, Utah where the Cholangiocarcinoma Foundation was founded. Dave Fleischer, a ... volunteer and supporter of the Cholangiocarcinoma Foundation (CCF), plans to spend 6 weeks driving across the country to raise ...
Cholangiocarcinoma | Anticancer Research
Eriodictyol Attenuates Cholangiocarcinoma Malignancy by Regulating HMOX1 Expression: An In Vitro Study JUNGWHOI LEE, WOOGWANG ... The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1 DA SOL LEE, SEONMIN LEE, CHORONG KIM ... Expression of FOXO4 Inhibits Cholangiocarcinoma Cell Proliferation In Vitro via Induction of G0/G1 Arrest KITTI INTUYOD, ... Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines UNCHALEE THONSRI, WUNCHANA SEUBWAI, SAKDA ...
Cholangiocarcinoma - Habib™ EndoHPB Radio Frequency Catheter - Boston Scientific - Boston Scientific
Liang et al., metal Stenting with or w/o Endobiliary RFA for Unresectable Extrahepatic Cholangiocarcinoma, Journal of Cancer ... Yang, Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: a randomized ... Healthcare professionals / Gastroenterology / HabibTM EndoHPB Bipolar Radiofrequency Catheter / Cholangiocarcinoma Stricture ...
Cholangiocarcinoma: Wayne's story | Roswell Park Comprehensive Cancer Center - Buffalo, NY
... cholangiocarcinoma is often discovered incidentally during other medical tests because it typically does not cause any ... As in Waynes case, cholangiocarcinoma is often discovered incidentally during other medical tests, because typically it does ... where a biopsy showed that he had cholangiocarcinoma, or bile duct cancer. ...
Cholangiocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032
10 Cholangiocarcinoma - Key Endpoints of Treatment. 11 Cholangiocarcinoma - Marketed Products. 11.1 List of Cholangiocarcinoma ... 8.1 Cholangiocarcinoma Guidelines, Management and Treatment. 8.2 Cholangiocarcinoma Treatment Algorithm. 9 Cholangiocarcinoma ... 12 Cholangiocarcinoma - Pipeline Drugs. 12.1 List of Cholangiocarcinoma Pipeline Drugs Across the Top 7 Markets. 12.1.1 Drug ... 15 Cholangiocarcinoma - Recent Events and Inputs From Key Opinion Leaders. 16 Cholangiocarcinoma Market - SWOT Analysis. 16.1 ...
Models of Intrahepatic Cholangiocarcinoma: Novel Tools and Therapeutic Applications - Oncology Nurse Advisor
Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy, and a number of recent studies have ... Models of Intrahepatic Cholangiocarcinoma: Novel Tools and Therapeutic Applications Margaret A. Hill, William B. Alexander, ... Abstract: Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy, and a number of recent studies ... Keywords: cholangiocarcinoma, biliary cancer, models, cell of origin, Cre-Lox, sleeping beauty ...
Cholangiocarcinoma - CheckOrphan
Keywords hepatobiliary + biliary + cholangiocarcinoma | PEIR Digital Library
Early Cholangiocarcinoma Detection with Magnetic Resonance Imaging in Primary Sclerosing Cholangitis | Mayo Clinic Connect
Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to ... Early Cholangiocarcinoma Detection with Magnetic Resonance Imaging in Primary Sclerosing Cholangitis. Share this:. ... Early Cholangiocarcinoma Detection with Magnetic Resonance Imaging in Primary Sclerosing Cholangitis. .ch-newsfeed-single-meta ... Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to ...
Ivosidenib Improves Overall Survival in Advanced IDH1+ Cholangiocarcinoma
... reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo. ... Cholangiocarcinoma is a rare, aggressive cancer of the bile ducts in and outside the liver. IDH1 mutations are found in an ... Prior to study entry, patients aged 18 years or older with IDH1-mutant cholangiocarcinoma had received 1 to 2 prior therapies, ... In the international, randomized, phase 3 ClarIDHy study, 187 previously treated patients with IDH1-mutant cholangiocarcinoma ...
Preoperative Evaluation of Hilar Cholangiocarcinoma with Contrast-enhanced Three-dimensional Fast Imaging with Steady-state...
Determination of hepatic arterial and/or portal invasion from cholangiocarcinoma was compared between MR angiography and DSA as ... angiography in patients with hilar cholangiocarcinoma, and to compare its efficacy with intraarterial digital subtraction ... 3D FISP MR angiography has the potential to replace DSA in the preoperative evaluation of hilar cholangiocarcinoma. We sought ... 3D FISP MR angiography has the potential to replace DSA in the preoperative evaluation of hilar cholangiocarcinoma. ...
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited - Projects - University of Edinburgh...
cholangiocarcinoma Archives - Drug Discovery and Development
Pemazyre offers promise for cholangiocarcinoma. Pemazyre (pemigatinib) from Innovent Biologics is a novel treatment for ... The indication covers unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 ... cholangiocarcinoma, a type of bile duct cancer. ...
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets | Journal of...
"Intrahepatic Cholangiocarcinoma Presenting as LI-RADS 5 "HCC"" by Raja K. Dhanekula, MD, Donald Mitchell, MD et al.
In contrast, intrahepatic cholangiocarcinoma (IHCC) is a contra-indication to liver transplantation due to high rates of ... In contrast, intrahepatic cholangiocarcinoma (IHCC) is a contra-indication to liver transplantation due to high rates of ... "Intrahepatic Cholangiocarcinoma Presenting as LI-RADS 5 HCC" (2016). Division of Gastroenterology and Hepatology Posters. ...
Perihilar cholangiocarcinomaIntrahepatic cholangiocarcinomasDistal2021MetastaticEpidemiologyKlatskinHilar cholangiocarcinomaUnresectable cholangiocarcinomaHepatobiliaryMalignancySymptoms of cholangiocarcinoma includeConfirming a diagnosis of cholangiocarcinomaRisk factors for cholangiocarcinomaDiagnosisHepatocellularTumorIncidence of cholangiocarcinomaLocally AdvancedType of bile duct cSmall intestineGallbladderAdjuvant ChemotherapyAbstractCancersSurgeryPreviously treatedIDH1PancreaticUlcerative colitisCancerPalliative treatmentTreatmentSurgicalMutationsPathogenesisCommon hepaTherapiesResectionJaundiceCytologicallyGenetic alterationsBiliary duct system
- Perihilar cholangiocarcinoma (also known as a Klatskin tumor) begins in an area called the hilum, where the right and left major bile ducts join and leave the liver. (medlineplus.gov)
- Perihilar cholangiocarcinoma , or Klatskin tumor . (upmc.com)
- This type is found outside the liver and also called perihilar cholangiocarcinoma or Klatskin tumor. (vejthani.com)
- Perihilar bile duct cancer is also called a Klatskin tumor or perihilar cholangiocarcinoma. (karmanos.org)
- Early detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify those patients eligible for curative therapy. (mayoclinic.org)
- It is shown that multidetector-row computed tomography is useful in assessing cancer invasion of the portal vein bifurcation by perihilar cholangiocarcinoma. (semanticscholar.org)
- Bismuth classification for perihilar cholangiocarcinoma. (medscape.com)
- Calcifications occur in 18% of intrahepatic cholangiocarcinomas. (medscape.com)
- Intrahepatic bile duct cancers are also called intrahepatic cholangiocarcinomas. (karmanos.org)
- The remaining cases are classified as distal cholangiocarcinomas, which begin in bile ducts outside the liver. (medlineplus.gov)
- Major hepatectomy was performed for patients with intrahepatic cholangiocarcinoma and proximal type of extrahepatic cholangiocarcinoma, while surgical procedures for patients with distal cholangiocarcinoma were subjected to pancreaticoduodenectomy. (medscape.com)
- Patients with cholangiocarcinoma have five-year survival rates of up to 20% for proximal lesions and 20-30% for distal lesions [ 4 ]. (biomedcentral.com)
- What was the country-wise size of the Cholangiocarcinoma market across the seven major markets in 2021 and how will it look like in 2032? (imarcgroup.com)
- The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets (Tibsovo) achieved a 21% reduction in the risk of death in patients with IDH1 -mutant cholangiocarcinoma compared with placebo, according to results presented during the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Symposium. (targetedonc.com)
- At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. (theoncologypharmacist.com)
- The indication covers unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. (drugdiscoverytrends.com)
- Metastatic pancreatic ductal adenocarcinoma and primary cholangiocarcinoma are morphologically very similar and, therefore, challenging to distinguish in liver biopsies. (elsevier.com)
- We hypothesized that the combination of our new marker and N-cadherin can assist in distinguishing metastatic pancreatic cancer from cholangiocarcinoma. (elsevier.com)
- The epidemiology of cholangiocarcinoma is still somewhat opaque, but we know that such diseases as primary biliary sclerosis, a relatively rare inflammatory condition, cause a narrowing of the bile duct system that is associated with increased risk. (medscape.com)
- Statement of the Problem & Purpose: Epidemiology of cholangiocarcinoma (CCA) is high in Thailand and Southeast Asia. (tsijournals.com)
- Portal cholangiocarcinoma: epidemiology, staging principles and aspects of tumor biology]. (wjgnet.com)
- Imaging and surgical workups showed hilar cholangiocarcinoma (Klatskin tumor). (ceon.rs)
- We sought to evaluate the image quality of double-dose, contrast-enhanced 3D fast imaging with steady-state precession (FISP) magnetic resonance (MR) angiography in patients with hilar cholangiocarcinoma, and to compare its efficacy with intraarterial digital subtraction angiography (DSA). (semanticscholar.org)
- Hilar cholangiocarcinoma: MR correlation with surgical and histological findings. (semanticscholar.org)
- Tojima Y , Nagino M, Ebata T, Uesaka K, Kamiya J, Nimura Y. Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with otherwise node-negative hilar cholangiocarcinoma. (wjgnet.com)
- The Landmark Series: Hilar Cholangiocarcinoma. (wjgnet.com)
- Extended lymphadenectomy in hilar cholangiocarcinoma: What it will bring? (wjgnet.com)
- Lymph Node Micrometastases are Associated with Worse Survival in Patients with Otherwise Node-Negative Hilar Cholangiocarcinoma. (wjgnet.com)
- Advances in diagnosis and treatment of hilar cholangiocarcinoma -- a review. (wjgnet.com)
- Medscape: What is the standard of care for unresectable cholangiocarcinoma? (medscape.com)
- The authors evaluated the activity and toxicity of docetaxel given as a 1-hour infusion every 21 days in patients with unresectable cholangiocarcinoma. (nih.gov)
- In the absence of detection of liver flukes, there is no test available that can determine if liver fluke infection is the underlying cause of cholangiocarcinoma or other hepatobiliary conditions. (cdc.gov)
- Cholangiocarcinoma is a slow-growing malignancy of the bile duct and is the second most common primary hepatic tumor after hepatoma. (medscape.com)
- Abstract: Intrahepatic cholangiocarcinoma (iCCA) is the second most common hepatic malignancy, and a number of recent studies have identified an increasing trend in incidence and mortality. (oncologynurseadvisor.com)
- Cholangiocarcinoma (CCA), a malignancy of bile duct epithelia, is a rare cancer worldwide but has high incidence in Khon Kaen province, Thailand. (tci-thaijo.org)
Symptoms of cholangiocarcinoma include1
- The symptoms of cholangiocarcinoma include jaundice , weight loss , and sometimes generalized itching . (bionity.com)
Confirming a diagnosis of cholangiocarcinoma1
- Angiographic findings alone are poor in confirming a diagnosis of cholangiocarcinoma because the features may occur in both hepatocellular and pancreatic malignancies. (medscape.com)
Risk factors for cholangiocarcinoma5
- Researchers have also investigated inherited variations in several genes as possible risk factors for cholangiocarcinoma. (medlineplus.gov)
- Several non-genetic risk factors for cholangiocarcinoma have been identified. (medlineplus.gov)
-  Risk factors for cholangiocarcinoma include primary sclerosing cholangitis (an inflammatory disease of the bile ducts), congenital liver malformations, infection with the parasitic liver flukes Opisthorchis viverrini or Clonorchis sinensis , and exposure to Thorotrast (thorium dioxide), a chemical previously used in medical imaging . (bionity.com)
- improved diagnostic methods may be partially responsible, but the prevalence of potential risk factors for cholangiocarcinoma, such as HIV infection , has also been increasing during this time frame. (bionity.com)
- Understanding of the significant genetic risk factors for Cholangiocarcinoma (CC) remains limited. (bvsalud.org)
- Dr. Kerr discussed with Medscape current issues in the diagnosis and management of cholangiocarcinoma. (medscape.com)
- Early detection and diagnosis of cholangiocarcinoma can increase the outcome of the treatment. (vejthani.com)
- Several immunohistochemical markers have been evaluated to aid this diagnosis, but aside from N-cadherin, which labels cholangiocarcinoma, few provide the combination of good sensitivity and specificity. (elsevier.com)
- We identified patients who received a diagnosis of cholangiocarcinoma (CC) from the Taiwan Cancer Registry between 2003 and 2009. (elsevier.com)
- Ultra-sensitive and cost-effective method for early stage hepatocellular carcinoma and intrahepatic cholangiocarcinoma detection using plasma cfDNA. (esmo.org)
- Early detection of primary liver cancer (PLC), including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), is essential for patients' survival. (esmo.org)
- Each year, approximately 2500 cases of cholangiocarcinoma occur, compared with 5000 cases of gallbladder cancer and 15,000 cases of hepatocellular cancer. (medscape.com)
- Overlapping signature genes between hepatocellular carcinoma and intrahepatic cholangiocarcinoma. (cdc.gov)
- In most cases of cholangiocarcinoma, these genetic changes are acquired during a person's lifetime and are present only in the bile duct cells that give rise to the tumor. (medlineplus.gov)
- The most common symptom of cholangiocarcinoma is jaundice (yellowing of the eyes and skin), which occurs when bile ducts are blocked by the tumor. (bionity.com)
- Cholangiocarcinoma, malignant tumor of epithelial cells of bile ducts has poor overall survival and prognosis. (ceon.rs)
- We report a case of non-resectable cholangiocarcinoma with a 57-month survival after incomplete R2 surgical margin resection of the tumor. (ceon.rs)
- Objective: Focal adhesion kinase (FAK) expression has been linked to tumor cell invasion and metastasis, but its role in intrahepatic cholangiocarcinoma (ICC) has not been addressed. (elsevier.com)
- Tumor maligno que se origina en el del epitelio de los CONDUCTOS BILIARES. (bvsalud.org)
Incidence of cholangiocarcinoma2
- The incidence of cholangiocarcinoma is only 1-2 per 100,000 persons, so no population screening program would be even remotely cost-effective. (medscape.com)
- The incidence of cholangiocarcinoma increases with age, and the disease is slightly more common in men than in women (possibly due to the higher rate of primary sclerosing cholangitis , a major risk factor, in men). (bionity.com)
- However, it seems that partial resection along with stent embedding and applied adjuvant chemotherapy in cases of locally advanced non-resectable cholangiocarcinoma may increase survival rate. (ceon.rs)
Type of bile duct c1
- Pemazyre (pemigatinib) from Innovent Biologics is a novel treatment for cholangiocarcinoma, a type of bile duct cancer. (drugdiscoverytrends.com)
- Cholangiocarcinoma is a cancer of the bile ducts , which drain bile from the liver into the small intestine . (bionity.com)
- Cholangiocarcinoma (CCA) represents a group of heterogeneous cancers that originate in the bile ducts that connect the liver and gallbladder to the small intestine. (theoncologypharmacist.com)
- however, the association of gallstones with cholangiocarcinoma is less marked than it is with carcinoma of the gallbladder. (medscape.com)
- Cholangiocarcinoma (CCA) is a rare cancer of the biliary duct system, which is comprised of the gallbladder and bile ducts. (cdc.gov)
- I don't think that there is yet a proven role for either adjuvant chemotherapy or adjuvant radiation therapy in cholangiocarcinoma. (medscape.com)
- abstract = "Background: The influence of morphological status on the long-term outcome of patients undergoing liver resection for intrahepatic cholangiocarcinoma (ICC) is poorly defined. (elsevier.com)
- abstract = "Diabetes mellitus (DM) has been associated with an increased risk of extrahepatic cholangiocarcinoma (ECC) and intrahepatic cholangiocarcinoma (ICC). (elsevier.com)
- Cholangiocarcinoma is a group of cancers that begin in the bile ducts. (medlineplus.gov)
- 0001). HPC2 was observed in 80% of pancreatic cancers (48/60), 82% of ampullary (9/11), and 32% (10/31) of cholangiocarcinomas. (elsevier.com)
- Bile duct cancer surgery is usually the recommended form of treatment for cholangiocarcinoma. (moffitt.org)
- When is surgery recommended for cholangiocarcinoma? (moffitt.org)
- Moffitt Cancer Center has surgeons who specialize in treating cholangiocarcinoma and are highly skilled and experienced in performing the latest techniques in bile duct cancer surgery. (moffitt.org)
- Surgery for extrahepatic cholangiocarcinoma: predictors of survival. (wjgnet.com)
- Witzigmann H , Lang H , Lauer H . Guidelines for palliative surgery of cholangiocarcinoma. (wjgnet.com)
- In the international, randomized, phase 3 ClarIDHy study, 187 previously treated patients with IDH1-mutant cholangiocarcinoma were randomized 2:1 to receive oral ivosidenib at 500 mg daily (n= 126) or placebo (n = 61). (targetedonc.com)
- Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 ( IDH1 ) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. (theoncologypharmacist.com)
- Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. (researchtopractice.com)
- Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 ( IDH1 ) mutation. (researchtopractice.com)
- The final overall survival analysis of the phase 3 ClarIDHy trial demonstrated that treatment with ivosidenib tablets achieved a 21% reduction in the risk of death in patients with IDH1-mutant cholangiocarcinoma compared with placebo. (targetedonc.com)
- The ClarIDHy study represents the first phase 3 study of a targeted, oral therapeutic with a noncytotoxic mechanism of action in advanced IDH1 -mutant cholangiocarcinoma," lead study author Andrew X. Zhu, MD, director of Liver Cancer Research at Massachusetts General Hospital, and professor of medicine at Harvard Medical School, said in a virtual presentation during the meeting. (targetedonc.com)
- IDH1 mutations are found in an estimated 20% of intrahepatic cholangiocarcinoma cases. (targetedonc.com)
- Prior to study entry, patients aged 18 years or older with IDH1 -mutant cholangiocarcinoma had received 1 to 2 prior therapies, including 1 gemcitabine- or 5-fluorouracil-containing regimen. (targetedonc.com)
- We immunostained resections of 60 pancreatic ductal adenocarcinomas and 31 cholangiocarcinomas for the HPC2 and N-cadherin antigens. (elsevier.com)
- We conclude that HPC2 and N-cadherin significantly improve accurate classification of pancreatic cancer and cholangiocarcinoma. (elsevier.com)
- For extrahepatic strictures due to resectable pancreatic cancer or cholangiocarcinoma, the ACG does not recommend routine preoperative biliary drainage. (medscape.com)
- The incidence of cholangiocarcinomas in patients with ulcerative colitis is 0.4-1.4%, with a latent period of 15 yr. (medscape.com)
- Intrahepatic cholangiocarcinoma may be associated with chronic ulcerative colitis and chronic cholecystitis . (medscape.com)
- The three types of cholangiocarcinoma do not usually cause any symptoms in their early stages, and this cancer is usually not diagnosed until it has already spread beyond the bile ducts to other tissues. (medlineplus.gov)
- Identifying somatic mutations in cholangiocarcinoma may provide clues to how quickly the cancer will grow and spread, and which treatments might be most effective. (medlineplus.gov)
- A retrospective study was conducted among newly diagnosed cholangiocarcinoma cancer patients, who underwent curative resection in Srinakarind Hospital, Khon Kaen University (a 1000-bed university hospital), Khon Kaen, Thailand, during January 2009-December 2011. (medscape.com)
- In part to advance research on and treatment of cholangiocarcinoma, Dr. Kerr and Professor Vinod Raina, from the All India Institute of Medical Sciences in Delhi, founded INDOX, an international research collaboration between the University of Oxford and 12 of India's leading comprehensive cancer centers, to provide basic research and translational science. (medscape.com)
- It is a relatively rare cancer, with an annual incidence of 1-2 cases per 100,000 in the Western world,  but rates of cholangiocarcinoma have been rising worldwide over the past several decades. (bionity.com)
- Intrahepatic cholangiocarcinoma is cancer that grows in the bile ducts inside the liver . (upmc.com)
- Cholangiocarcinoma also known as bile duct cancer commonly be found in people 50 years old and above. (vejthani.com)
- Dave Fleischer, a volunteer and supporter of the Cholangiocarcinoma Foundation (CCF), plans to spend 6 weeks driving across the country to raise awareness of cancer that claimed the life of his daughter, Sarah Bennett. (utahstories.com)
- After a liver biopsy at another hospital was deemed inconclusive, Wayne quickly made an appointment at Roswell Park, where a biopsy showed that he had cholangiocarcinoma, or bile duct cancer. (roswellpark.org)
- Cholangiocarcinoma is a type of cancer involving the mutation of epithelial cells in the bile ducts. (imarcgroup.com)
- Cholangiocarcinoma is a rare, aggressive cancer of the bile ducts in and outside the liver. (targetedonc.com)
- Cholangiocarcinoma (CCA) is the second most common primary liver cancer, characterized by a poor prognosis and resistance to chemotherapeutics. (bvsalud.org)
- Most carcinogenicity data centre on the possibility that these trematodes are involved in the development of cholangiocarcinoma or liver cancer. (who.int)
- After the sudden, rapid decline and death of my mother from cholangiocarcinoma (very rare yet aggressive form of cancer) on June 15, 2005, I decided to start my private practice as a doula to the dying and their families. (certifiedcaredoula.com)
- Biliary drainage and stent placement remains to be the main palliative treatment choice for advanced perihiliar cholangiocarcinoma (pCCA), and the life expectancy is only 4-6 months. (centerwatch.com)
- According to the report, among the seven major markets, the United States has the largest patient pool for Cholangiocarcinoma and also represents the largest market for Cholangiocarcinoma treatment. (imarcgroup.com)
- A Cell viability was analyzed in SDHAF2 depletion and overexpression cholangiocarcinoma cells after treatment with CDDP. (biomedcentral.com)
- Unless we can diagnose cholangiocarcinoma early and recommend complete surgical resection, there is no curative therapy. (medscape.com)
- MR imaging and MRCP are able to detect and preoperatively assess patients with cholangiocarcinoma, investigating all involved structures such as bile ducts, vessels and hepatic parenchyma, and the main reason for surgical/imaging discrepancy is represented by microscopic diffusion along the mucosa and in the perineural space. (semanticscholar.org)
- Complete surgical resection is the only therapy to afford a chance of cure for cholangiocarcinoma. (medscape.com)
- Somatic mutations in many different genes have been found in cholangiocarcinoma. (medlineplus.gov)
- Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses recent developments in the use of targeted theapies for these patients, including the differences between genetic alterations in intrahepatic and extrahepatic cholangiocarcinoma and which targetable mutations could have the biggest therapeutic potential. (vjoncology.com)
- Results of some epidemiologic studies have implicated bacteria-induced carcinogens derived from bile salts (eg, lithocholate) as a causative factor in the pathogenesis of cholangiocarcinomas . (medscape.com)
- Extrahepatic cholangiocarcinoma starts in the bile ducts outside the liver , including the common hepatic duct and the cystic duct. (upmc.com)
- Areas of ongoing medical research in cholangiocarcinoma include the use of newer targeted therapies (such as erlotinib ) and the use of photodynamic therapy . (bionity.com)
- Cholangiocarcinoma Market is currently driven by factors such as a rising geriatric population, increasing number of patients with liver disease, a large smoking population, growing number of patients with diabetes, and rising safety and efficacy of current and emerging therapies, etc. (imarcgroup.com)
- Approximately 40% of patients with cholangiocarcinoma have genetic alterations for which targeted therapies already exist. (vjoncology.com)
- For perihilar strictures due to cholangiocarcinoma in cases where resection or transplantation is not possible, adjuvant endobiliary ablation (photodynamic therapy or radiofrequency ablation) plus plastic stent placement is recommended over plastic stent placement alone. (medscape.com)
- patients with cholangiocarcinoma in the extrahepatic bile ducts (outside the liver) are more likely to have jaundice, while those with tumors of the bile ducts within the liver often have pain without jaundice. (bionity.com)
- Seventeen patients with cytologically or histologically confirmed cholangiocarcinoma received intravenous docetaxel over 1 hour, repeated every 21 days. (nih.gov)
- Practical considerations in screening for genetic alterations in cholangiocarcinoma. (researchtopractice.com)
Biliary duct system1
- Cholangiocarcinomas (CCCs) are malignancies of the biliary duct system that may originate in the liver and extrahepatic bile ducts, which terminate at the ampulla of Vater. (medscape.com)